

10/27/00



JC852 U.S. PTO

10-30-00

A

ATTY. DOCKET NO. 25436/1560

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Joseph A. Sorge et al.)	Examiner: Not assigned yet
)	
Serial No.: Not assigned Yet)	Art Unit: Not assigned yet
)	
Filed: Concurrent Herewith)	
)	
For: COMPOSITIONS AND METHODS)	
UTILIZING DNA POLYMERASES)	



Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

TRANSMITTAL LETTER


Enclosed for filing in the above-identified patent, please find the following documents:

1. Certificate of Express Mailing;
2. New Patent Application Transmittal;
3. Patent Application Specification (116 Pages);
4. 17 Sheets of Informal Drawings;
5. Executed Declaration and Power of Attorney;
6. Executed Small Entity Statement;
7. Check in the amount of \$2,136.00 for the Requisite Filing Fee; and,
8. Return Post Card.

The Assistant Commissioner for Patents is hereby authorized to charge any additional fees or credit any overpayment in the total fees to Deposit Account No. 16-0085, Reference No: 25436/1560. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

10/27/00
Date


Kathleen M. Williams, Esq.
Reg. No. 34,380
PALMER AND DODGE, LLP
One Beacon Street
Boston, MA 02109-3190
Telephone No: (617) 573-0451
Fax No: (617) 227-4420

The PTO did not receive the following
listed item(s) 10 Sheets of Specification
1 REC 99 Sheets

NEW UNITED STATES UTILITY PATENT APPLICATION
under 37 C.F.R. 1.53(b)

Page 1

Atty. Docket No 25436/1560

JCS53 U.S. PTO
09/698341
10/27/00

CERTIFICATE OF EXPRESS MAILING UNDER 37 C.F.R. § 1.10: The undersigned hereby certifies that this United States Patent application and all papers noted herein as being attached, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 today, **October 27, 2000** and is addressed to: Box: Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Express Mail No: EL591995250US


Kathleen M. Williams, Ph.D

Assistant Commissioner of Patents
Patent Applications
Washington, D.C. 20231

Attorney Docket No: 25436/1560

Enclosed herewith is a new patent application and the following papers:

First Named Inventor (or application identifier): **Joseph A. Sorge, Holly Hurlbut Hogrefe and Connie Hansen**

Title of Invention: **"COMPOSITIONS AND METHODS UTILIZING DNA POLYMERASES"**

1. ☒ Specification 116 pages (including specification, claims, abstract) / **154** claims (**14** independent)
2. ☒ Declaration/Power of Attorney is:
☒ attached in the regular manner (Executed).
☐ NOT included, but deferred under 37 C.F.R. § 1.53(f).
3. ☒ 17 Distinct sheets of ☐ Formal ☒ Informal Drawings
4. ☐ Preliminary Amendment.
5. ☐ Information Disclosure Statement
☐ Form 1449
☐ A copy of each cited prior art reference
6. ☐ Assignment with Cover Sheet.
7. ☒ Priority is hereby claimed under 35 U.S.C. § 119 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)
U.S.	60/162,600	29 October 1999

- ☐ Priority is hereby claimed under 35 U.S.C. § 120 based upon the following application(s):

Country	Application Number	Date of Filing (day, month, year)

8. ☐ Priority document(s).
9. ☒ Statement Claiming Small Entity Status (Executed).
10. ☐ Microfiche Computer Program (Appendix).

NEW UNITED STATES UTILITY PATENT APPLICATION
under 37 C.F.R. 1.53(b)

Page 2

Atty. Docket No25436/1560

11. ☐ Nucleotide and/or Amino Acid Sequence Submission.
☐ Computer Readable Copy.
☐ Paper Copy (identical to computer copy).
☐ Statement verifying identity of above copies.

12. Calculation of Fees:

FEES FOR	EXCESS CLAIMS	FEE	AMOUNT DUE
Basic Filing Fee (37 C.F.R. § 1.16(a))			
			\$710.00
Total Claims in Excess of 20 (37 C.F.R. § 1.16(c))	134	134.00	\$2412.00
Independent Claims in Excess of 3 (37 C.F.R. § 1.16(b))	11	80.00	\$880.00
Multiple Dependent Claims (37 C.F.R. § 1.16(d))	Y	270.00	\$270.00
Subtotal - Filing Fee Due			\$4272.00
REDUCE BY (%) (\$)			
Reduction by 50%, if Small Entity (37 C.F.R. §§ 1.9, 1.27, 1.28)	0.50		\$2136.00
TOTAL FILING FEE DUE			\$0.00
Assignment Recordation Fee (if applicable) (37 C.F.R. § 1.21(h))	0	40.00	\$0.00
GRAND TOTAL DUE			\$2,136.00


PAYMENT is:

☒ included in the amount of the GRAND TOTAL by our enclosed check.

All correspondence for the attached application should be directed to:

PALMER& DODGE, LLP
One Beacon Street
Boston, MA 02108-3190

Date: October 27, 2000

By 
Kathleen M. Williams, Ph.D
Reg. No. 34,380

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No: 25436/1560

Applicant or Patentee: Joseph A. Sorge, Holly Hurlbut Hogrefe and Connie Jo Hansen

Serial No.: Not Assigned Yet

Filed: Concurrent Herewith

Entitled: "Compositions and Methods Utilizing DNA Polymerases"

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(d) AND 1.27(d)) -SMALL BUSINESS CONCERN**

I hereby declare that I am an official empowered to act on behalf of the small business concern identified below:

Name of Organization: **Stratagene**

Address of Organization: **11011 North Torrey Pines Road
La Jolla, CA 92037**

I hereby declare that the small business concern identified above qualifies as a small business concern as defined in 37 C.F.R. § 1.9(d) for purposes of paying reduced fees under § 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled

Compositions and Methods Utilizing DNA Polymerases

by inventor(s) Joseph A. Sorge, Holly Hurlbut Hogrefe & Connie Jo Hansen
described in

- ☐ the specification filed herewith
☒ Application Serial No. 60/162,600 filed October 29, 1999
☐ Patent No. _____, issued _____.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern with regard to the above-identified invention.

If the rights held by the above identified small business concern are not exclusive, each individual concern or organization having rights in the invention is listed below* and no rights to the invention are held by any

made the invention, or by any concern which would not qualify as a small business concern under 37 CFR § 1.9(d), or a nonprofit organization under 37 CFR § 1.9(e).

Ronni Sherman

NAME OF PERSON SIGNING


Executive Vice President & General Counsel

TITLE IN ORGANIZATION

STRATAGENE

11011 North Torrey Pines Road, La Jolla, CA 92037

COMPANY



SIGNATURE

10/18/20

DATE

COMPOSITIONS AND METHODS UTILIZING DNA POLYMERASES

ABSTRACT OF THE DISCLOSURE

The invention features a novel isolated Family B DNA polymerase, a *Thermococcus* polymerase JDF-3, and mutant recombinant forms thereof. Mutant polymerases of the invention are deficient in 3' to 5' exonuclease activity and/or exhibit reduced discrimination against non-conventional nucleotides relative to the wild-type form of the polymerase.

FIELD OF THE INVENTION

The present invention relates to compositions and methods utilizing DNA polymerase enzymes with reduced discrimination for non-conventional nucleotides. The enzymes of the invention are useful in many applications calling for the detectable labeling of nucleic acids and are particularly useful in DNA sequencing applications.

BACKGROUND OF THE INVENTION

Detectable labeling of nucleic acids is required for many applications in molecular biology, including applications for research as well as clinical diagnostic techniques. A commonly used method of labeling nucleic acids uses one or more unconventional nucleotides and a polymerase enzyme that catalyzes the template-dependent incorporation of the unconventional nucleotide(s) into the newly synthesized complementary strand.

The ability of a DNA polymerase to incorporate the correct deoxynucleotide is the basis for high fidelity DNA replication in vivo. Amino acids within the active site of polymerases form a specific binding pocket that favors the placement of the correct complementary nucleotide opposite the template nucleotide. If a mismatched nucleotide, ribonucleotide, or nucleotide analog fills that position, the precise alignment of the amino acids contacting the

incoming nucleotide may be distorted into a position unfavorable for DNA polymerization. Because of this, the unconventional nucleotides or nucleotide analogs used to label DNA tend to be incorporated into the elongated strand less efficiently than do the standard deoxynucleotide triphosphates (dNTPs; the so-called “standard” dNTPs include deoxyadenosine triphosphate (dATP), deoxycytosine triphosphate (dCTP), deoxyguanosine triphosphate (dGTP), and thymidine triphosphate (TTP)).

The reduced efficiency with which unconventional nucleotides are incorporated by the polymerase increases the amount of the unconventional nucleotide necessary for DNA labeling. The reduced efficiency of incorporation of a particular nucleotide can also adversely affect the performance of techniques or assays, such as DNA sequencing, that depend upon unbiased incorporation of unconventional nucleotides for homogeneous signal strength.

The identity and exact arrangement of the amino acids of a DNA polymerase that contact an incoming nucleotide triphosphate determine the nature of the nucleotides, both conventional and unconventional, that may be incorporated by that polymerase enzyme. Changes in the exact placement of the amino acids that contact the incoming nucleotide triphosphate at any stage of binding or chain elongation can dramatically alter the polymerase’s capacity for utilization of unusual or unconventional nucleotides. Sometimes changes in distant amino acids can influence the incorporation of nucleotide analogs due to indirect global or structural effects. Polymerases with increased capacity to incorporate nucleotide analogs are useful for labeling DNA or RNA strands with nucleotides modified with signal moieties such as dyes, reactive groups or unstable isotopes.

In addition to labeled nucleotides, an extremely important class of modified nucleotides is the dideoxynucleotides. The so-called “Sanger” or “dideoxy” DNA sequencing method (Sanger et al., 1977, Proc. Natl. Acad. Sci. USA 74: 5463, which is incorporated herein by

reference) relies upon the template-directed incorporation of nucleotides onto an annealed primer by a DNA polymerase from a mixture containing deoxy- and dideoxynucleotides. The incorporation of a dideoxynucleotide results in chain termination, the inability of the enzyme to catalyze further extension of that strand. Electrophoretic separation of reaction products results in a “ladder” of extension products wherein each extension product ends in a particular dideoxynucleotide complementary to the nucleotide opposite it in the template. The distance of the dideoxynucleotide analog from the primer is indicated by the length of the extension product. When four reactions, each containing one of the four dideoxynucleotide analogs ddA, ddC, ddG, or ddT (ddNTPs) are separated on the same gel, the sequence of the template may be read directly from the ladder patterns. Extension products may be detected in several ways, including for example, the inclusion of isotopically- or fluorescently-labeled primers, deoxynucleotide triphosphates or dideoxynucleotide triphosphates in the reaction.

Fluorescent labeling has the advantages of faster data collection, since detection may be performed while the gel is running, and longer reads of sequence data from a single reaction and gel. Further, fluorescent sequence detection has allowed sequencing to be performed in a single reaction tube containing four differentially-labeled fluorescent dye terminators (the so-called dye-terminator method, Lee et al., 1992, Nucleic Acids Res. 20: 2471, incorporated herein by reference).

A desirable quality of a polymerase useful for DNA sequencing is improved incorporation of dideoxynucleotides. Improved incorporation of dideoxynucleotides can make processes such as DNA sequencing more cost effective by reducing the requirement for expensive radioactive or fluorescent dye-labeled dideoxynucleotides. Moreover, unbiased dideoxynucleotide incorporation provides improved signal uniformity, leading to increased accuracy of base determination. The even signal output further allows subtle sequence

differences caused by factors like allelic variation to be detected. Allelic variation, which produces two different half strength signals at the position of relevance, can easily be concealed by the varied signal strengths caused by polymerases with non-uniform ddNTP utilization.

Incorporation of ribonucleotides by the native form of DNA polymerase is a rare event. Mutants that incorporate higher levels of ribonucleotides can be used for applications such as sequencing by partial ribosubstitution. In this system, a mixture of ribonucleotides and deoxynucleotides corresponding to the same base are incorporated by the mutant polymerase (Barnes, 1978 J. Mol. Biol. 119:83-99). When the ribosequencing reactions are exposed to alkaline conditions and heat, fragmentation of the extended strand occurs. If the reactions for all four bases are separated on a denaturing acrylamide gel, they produce a sequencing ladder. There is a need in the art for polymerase mutants with higher utilization of ribonucleotides for this alternative method of sequencing.

Alternatively, the incorporation of ribonucleotides followed by alkaline hydrolysis could be utilized in a system that requires random cleavage of DNA molecules such as DNA shuffling ((Stemmer, 1994, Nature, 370: 389-391) which has also been called molecular breeding, sexual PCR and directed evolution).

Another desirable quality in a DNA labeling enzyme is thermal stability. DNA polymerases exhibiting thermal stability have revolutionized many aspects of molecular biology and clinical diagnostics since the development of the polymerase chain reaction (PCR), which uses cycles of thermal denaturation, primer annealing, and enzymatic primer extension to amplify DNA templates. The prototype thermostable DNA polymerase is Taq polymerase, originally isolated from the thermophilic eubacterium *Thermus aquaticus*. So-called “cycle sequencing” reactions using thermostable DNA polymerases have the advantage of requiring

smaller amounts of starting template relative to conventional (i.e., non-cycle) sequencing reactions.

There are three major families of DNA polymerases, termed families A, B and C. The classification of a polymerase into one of these three families is based on structural similarity of a given polymerase to *E. coli* DNA polymerase I (Family A), II (Family B) or III (family C). As examples, Family A DNA polymerases include, but are not limited to Klenow DNA polymerase, *Thermus aquaticus* DNA polymerase I (Taq polymerase) and bacteriophage T7 DNA polymerase; Family B DNA polymerases, formerly known as α -family polymerases (Braithwaite and Ito, 1991, Nuc. Acids Res. 19:4045), include, but are not limited to human α , δ and ϵ DNA polymerases, T4, RB69 and ϕ 29 bacteriophage DNA polymerases, and *Pyrococcus furiosus* DNA polymerase (Pfu polymerase); and family C DNA polymerases include, but are not limited to *Bacillus subtilis* DNA polymerase III, and *E. coli* DNA polymerase III α and ϵ subunits (listed as products of the *dnaE* and *dnaQ* genes, respectively, by Braithwaite and Ito, 1993, Nucleic Acids Res. 21: 787). An alignment of DNA polymerase protein sequences of each family across a broad spectrum of archaeal, bacterial, viral and eukaryotic organisms is presented in Braithwaite and Ito (1993, supra), which is incorporated herein by reference.

The term used to describe the tendency of DNA polymerases to not to carry the incorporation of unnatural nucleotides into the nascent DNA polymer is “discrimination”. In Family A DNA polymerases, the effective discrimination against incorporation of dideoxynucleotide analogs is largely associated with a single amino acid residue. The majority of enzymes from the Family A DNA polymerases have a phenylalanine (phe or F) residue at the position equivalent to F762 in *E. coli* Klenow fragment of DNA polymerase and demonstrate a strong discrimination against dideoxynucleotides. A few polymerases (e.g. T7 DNA

polymerase) have a tyrosine (tyr or Y) residue at the corresponding position and exhibit relatively weak discrimination against dideoxynucleotides. Family A polymerases with tyrosine at this position readily incorporate dideoxynucleotides at levels equal to or only slightly different from the levels at which they incorporate deoxynucleotides. Conversion of the tyrosine or phenylalanine residues in the site responsible for discrimination reverses the dideoxynucleotide discrimination profile of the Family A enzymes (Tabor and Richardson, 1995, Proc. Natl. Acad. Sci. USA 92:6449).

Among the thermostable DNA polymerases, a mutant form of the Family A DNA polymerase from *Thermus aquaticus*, known as AmpliTaq FS® (Perkin Elmer), contains a F667Y mutation at the position equivalent to F762 of Klenow DNA polymerase and exhibits increased dideoxynucleotide uptake (i.e., reduced discrimination against ddNTPs) relative to the wild-type enzyme. The reduced discrimination for dideoxynucleotide uptake makes it more useful for fluorescent and labeled dideoxynucleotide sequencing than the wild-type enzyme.

The F667Y mutant of Taq DNA polymerase is not suited, however, for use with fluorescein-labeled dideoxynucleotides, necessitating the use of rhodamine dye terminators. Rhodamine dye terminators that are currently utilized with Taq sequencing reactions, however, stabilize DNA secondary structure, causing compression of signal. Efforts to eliminate compression problems have resulted in systems that use high amounts of the nucleotide analog deoxyinosine triphosphate (dITP) in place of deoxyguanosine triphosphate. While incorporation of (dITP) reduces the compression of the signal, the presence of dITP in the reaction produces additional complications including lowered reaction temperatures and increased reaction times. Additionally, the use of rhodamine dyes in sequencing requires undesirable post-reaction purification (Brandis, 1999 Nuc. Acid Res. 27:1912).

Family B DNA polymerases exhibit substantially different structure compared to Family A DNA polymerases, with the exception of the position of acidic residues involved in catalysis in the so-called palm domain (Wang et al., 1997, Cell 89:1087; Hopfner et al., 1999, Proc. Natl. Acad. Sci. USA 96:3600). The unique structure of Family B DNA polymerases may permit a completely different spectrum of interactions with nucleotide analogs, perhaps allowing utilization of analogs which are unsuitable for use with Family A DNA polymerases due to structural constraints. Thermostable Family B DNA polymerases have been identified in hyperthermophilic archaea. These organisms grow at temperatures higher than 90°C and their enzymes demonstrate greater thermostability (Mathur et al., 1992, Strategies 5:11) than the thermophilic eubacterial Family A DNA polymerases. Family B polymerases from hyperthermophilic archaea may be well suited starting substrates for modification(s) to reduce discrimination against non-conventional nucleotides.

Although the crystal structures of three Family B DNA polymerases have been solved (Wang et al., 1997, supra; Hopfner, K.-P. et al., 1999, Proc. Natl. Acad. Sci. 96: 3600; Zhao, 1999, Structure Fold Des., 7:1189), the structures of DNA-polymerase or dNTP-polymerase co-complexes have not yet been reported. At present, identification of amino acid residues contributing to nucleotide analog discrimination can only be inferred from extrapolation to Family A-dNTP structures or from mutagenesis studies carried out with related Family B DNA polymerases (e.g., human pol α , phage T4, phage ϕ 29, *T. litoralis* DNA polymerase).

Sequence comparison of the Family B DNA polymerases indicate six conserved regions numbered I-VI (Braithwaite and Ito, 1993, supra). The crystal structure of bacteriophage RB69 DNA polymerase (Family B) proposed by Wang et al. (Wang et al., 1997, supra) shows that Y416 in region II (which corresponds to Y409 in the Family B DNA polymerase of *Thermococcus* species JDF-3) has the same position as Y115 in HIV reverse transcriptase (RT)

and E710 in the Klenow fragment (Family A polymerases). Modeling of the dNTP and primer template complex in RB69 was carried out using the atomic coordinates of the reverse transcriptase-DNA cocrystal. This model predicts the RB69 Y416 packs under the deoxyribose portion of the dNTP. Tyrosine at this position has been implicated in ribose selectivity, contributing to polymerase discrimination between ribonucleotides and deoxynucleotides in mammalian reverse transcriptases (Y115) (Gao et al., 1997, Proc. Natl. Acad. Sci. USA 94:407; Joyce, 1994, Proc. Natl. Acad. Sci. USA 94:1619) and in Family A DNA polymerases where modification of the corresponding invariable glutamate residue (E710) reduces discrimination against ribonucleotides (Gelfand et al., 1998, Pat. No. EPO823479; Astatke et al., 1998, Proc. Natl. Acad. Sci. USA 96:3402).

Mutagenesis studies done in Family B DNA polymerases also implicate the region containing the analogous Y in region II in dNTP incorporation and ribose selectivity. Mutations at the corresponding Y865 in human DNA polymerase α affect polymerase fidelity and sensitivity to dNTP nucleotide inhibitors such as AZT-TP, which has a bulky 3'-azido group in place of the 3'-OH group, BuPdGTP, which contains a butylphenyl group attached to the amino group at the C-2 position in the guanine base of dGTP (resulting in a bulkier and more hydrophobic purine base nucleotide) and aphidicolin, a competitive inhibitor of pyrimidine deoxynucleotide triphosphate. Interestingly, the mutants showed no difference in their uptake of ddCTP (Dong et al., 1993, J. Biol. Chem. 268: 26143). Additionally, mutants of bacteriophage T4 DNA polymerase, which have converted L412 to methionine (M) or isoleucine (I) just one amino acid before the analogous Y (Y411), show extreme and mild sensitivity, respectively, to the inorganic pyrophosphate analog phosphonoacetic acid (PAA). Alterations in PAA sensitivity have been shown to predict polymerase interactions with nucleotide analogs. L412 in T4 DNA polymerase corresponds to L410 in *Thermococcus* species JDF-3 DNA polymerase. The L412M

T4 DNA polymerase mutant was inhibited with 50-fold less ddGTP than wild-type polymerase while the K_m s for dGTP was similar. As stated by the authors in that study, “[d]espite the sensitivity of the L412M DNA polymerase to ddGTP, there was no difference found in the incorporation of ddNTPs by wild-type and L412M DNA polymerase.” (Reha-Krantz et al., 1993, J. Virol. 67:60). In bacteriophage ϕ 29, mutations in region II (LYP where Y is analogous to *Thermococcus* species JDF3 DNA polymerase Y409) produce mixed results when challenged with PAA; P255S was hypersensitive to PAA while L253V was shown to be less sensitive than the wild-type enzyme (Blasco et al., 1993, J. Biol. Chem. 268: 24106). These data support the role of the LYP region (region II) in polymerase-nucleotide interactions, but improved incorporation of ddNTPs was not achieved in these references.

In another study, extensive mutation of region II in the archaeal Family B DNA polymerase from *Thermococcus litoralis* DNA polymerase (VENTTM polymerase, New England Biolabs) was performed. In that study, 26 different site-directed mutants were made for the sole intent of examining nucleotide analog discrimination (Gardner and Jack, 1999, Nucleic Acids Res. 27: 2545). Site-directed mutagenesis of VENTTM DNA polymerase demonstrated that three mutations at Y412 (which corresponds to JDF-3 DNA polymerase Y409) could alter nucleotide binding (Gardner and Jack, 1999, supra). Y412V was most significant with a 2 fold increase in dideoxynucleotide incorporation and a 200 fold increase in the incorporation of ribonucleotide ATP. The mutation Y412F showed no change in analog incorporation.

Region III of the Family B polymerases (also referred to as motif B) has also been demonstrated to play a role in nucleotide recognition. This region, which corresponds to AA 487 to 495 of JDF-3 Family B DNA polymerase, has a consensus sequence KX₃NSXYG (Jung et al., 1990, supra; Blasco et al., 1992, supra; Dong et al., 1993, J. Biol. Chem. 268:21163; Zhu et al., 1994, Biochem. Biophys. Acta 1219:260; Dong and Wang, 1995, J. Biol. Chem. 270:21563), and

is functionally, but not structurally (Wang et al., 1997, *supra*), analogous to $KX_3(F/Y)GX_2YG$ in helix O of the Family A DNA polymerases. In Family A DNA polymerases, such as the Klenow fragment and Taq DNA polymerases, the O helix contains amino acids that play a major role in dNTP binding (Astatke et al., 1998, J. Mol. Biol. 278:147; Astatke et al., 1995, J. Biol. Chem. 270:1945; Polesky et al., 1992, J. Biol. Chem 267:8417; Polesky et al., 1990, J. Biol. Chem. 265:14579; Pandey et al., 1994, J. Biol. Chem. 269:13259; Kaushik et al., 1996, Biochem. 35:7256). Specifically, helix O contains the F (F763 in the Klenow fragment; F667 in Taq) which confers ddNTP discrimination in Family A DNA polymerases ($KX_3(\underline{F/Y})GX_2YG$) (Tabor and Richardson, 1995, *supra*).

Directed mutagenesis studies in region III of VENTTM DNA polymerase also targeted an alanine analogous to A485 of the *Thermococcus* species JDF-3 DNA polymerase (Jung et al., 1990, *supra*). These mutants (A→C, A→S, A→L, A→I, A→F and A→V) exhibited a range of specific activities from 0.12 to 1.2 times the polymerase activity of the progenitor enzyme (Gardner and Jack, 1999, Nucl. Acids Res. 27:2545). The dideoxynucleotide incorporation ranged from 4 to 15 times the unmutated enzyme. Interestingly, the mutant with the highest dideoxynucleotide incorporation (15x) had a specific activity of only 0.12x of the original enzyme.

Site-directed mutagenesis studies on the Family B DNA polymerase from *Thermococcus barossii* modified each residue independently in the sequence ILANSF, which corresponds to AA residues 488-493 of the JDF-3 DNA polymerase, to tyrosine (Reidl et al., U.S. Patent No. 5,882,904). That study indicated that an L489Y mutant exhibits approximately 3 times greater incorporation of dideoxynucleotides relative to an enzyme bearing the wild-type leucine residue at this site.

One area of active research involves the use of nucleic acid arrays, often referred to as nucleic acid or DNA “chips”, in the simultaneous analyses of multiple different nucleic acid sequences. Many of these applications, such as those described in U.S. Patent No. 5,882,904 (Reidl et al., issued March 16, 1999) will benefit from DNA polymerases exhibiting reduced discrimination against non-conventional nucleotides, particularly fluorescently-labeled non-conventional nucleotides. Applications being addressed in the chip format include DNA sequencing and mutation detection, among others. For example, the “mini-sequencing” methods (e.g., Pastinen et al., 1997, Genome Res. 7: 606; Syvanen, 1999, Human Mutation 13: 1-10) and the arrayed primer extension (APEX) mutation detection method (Shumaker et al., 1996, Hum. Mutat. 7: 346) and methods like them can benefit from DNA polymerases with reduced discrimination against fluorescently-labeled or other non-conventional nucleotides. There is a need in the art for a non-discriminating DNA polymerase for use in chip or gel based mini-sequencing systems. Such a system would advantageously permit detection of multiplexed single nucleotide polymorphisms (SNPs) and allow for quantitative genotyping. Identification of sequence variation permits the diagnosis and treatment of genetic disorders, predisposition to multifactorial diseases, and sensitivity to new or existing pharmaceutical products.

There is a need in the art for DNA polymerases with reduced discrimination against unconventional nucleotides. There is particularly a need in the art for thermostable DNA polymerases exhibiting reduced discrimination against dideoxynucleotides, and further, for DNA polymerases exhibiting reduced discrimination against fluorescently labeled dideoxynucleotides.

SUMMARY OF THE INVENTION

The present invention relates to compositions and methods utilizing DNA polymerase enzymes exhibiting reduced discrimination against non-conventional nucleotides. Enzymes with

this quality are useful in many applications calling for the detectable labeling of nucleic acids and are particularly useful in DNA sequencing applications.

The invention further relates to a Family B DNA polymerase having one or more mutations at a site or sites corresponding to L408, P410, S345, and/or A485 of SEQ ID NO: 2, or a fragment thereof which retains the ability to direct the template-dependent polymerization of nucleic acid. The invention also encompasses mutants and modified versions (e.g., reversibly inactivated versions of a Family B polymerase prepared, for example, by chemical modification or antibody complexing) of a Family B polymerase mutated at sites corresponding to L408, P410 and or A485 of SEQ ID NO: 2.

In one embodiment, the DNA polymerase has a dual mutation comprising comprising a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2; and a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

The invention encompasses purified thermostable DNA polymerase having an amino acid sequence presented in SEQ ID NO: 2 from residue 1 to 776.

In one embodiment, the thermostable DNA polymerase is isolated from *Thermococcus* species JDF-3.

In another embodiment, the thermostable polymerase is isolated from a recombinant organism transformed with a vector that codes for the expression of *Thermococcus* species JDF-3 DNA polymerase.

The invention further encompasses a recombinant vector comprising the nucleotide sequence presented in SEQ ID NO: 1.

The invention further encompasses an isolated recombinant polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or a functional fragment thereof.

The invention further encompasses an isolated recombinant DNA polymerase from *Thermococcus* species JDF-3 that is 3' to 5' exonuclease deficient.

In one embodiment, the isolated recombinant DNA polymerase of has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2 or a glutamic acid to alanine mutation at the amino acid corresponding to E143 of SEQ ID NO: 2.

In another embodiment, the isolated recombinant DNA polymerase has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2 and a glutamic acid to alanine mutation at the amino acid corresponding to E143 of SEQ ID NO: 2.

The invention further encompasses an isolated recombinant DNA polymerase having reduced discrimination against non-conventional nucleotides.

In one embodiment, the DNA polymerase is a Family B DNA polymerase.

In another embodiment, the DNA polymerase further comprises a mutation selected from the group consisting of: a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2; a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2; a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2; and an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2.

The invention further encompasses an isolated recombinant DNA polymerase having the alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO:2 further comprising a mutation selected from the group consisting of: a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2; a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2; and a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

The invention further encompasses an isolated recombinant DNA polymerase having the a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2, further comprising of serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2

In another embodiment, the DNA polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides and conjugated nucleotides.

In another embodiment, conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

The invention further encompasses an isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 of SEQ ID NO: 2, wherein the DNA polymerase has reduced discrimination against non-conventional nucleotides relative to the wild-type form of that polymerase.

In one embodiment, the Family B DNA polymerase is 3' to 5' exonuclease deficient.

In another embodiment, the Family B DNA polymerase has a mutation at an amino acid corresponding to D141 or E143 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase has an aspartic acid to threonine or alanine mutation at a site corresponding to D141 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase has a glutamic acid to alanine mutation at a site corresponding to E143 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase has a glutamic acid to alanine mutation at a site corresponding to E143 of SEQ ID NO: 2 and has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase is thermostable.

In another embodiment, the Family B DNA polymerase is archaeal.

In another embodiment, the Family B DNA polymerase comprises a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 comprises a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 comprises a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 comprises a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprising a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2, further having a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2, and may further comprise a mutation at a site corresponding to T604 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a tyrosine to cysteine mutation at a site corresponding to Y497 of SEQ ID NO: 2, and may further comprise an isoleucine to valine mutation at a site corresponding to I630 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a glutamic acid to lysine mutation at a site corresponding to E645 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a glutamic acid to lysine mutation at a site corresponding to E578 of SEQ ID NO: 2, and may further comprise an arginine to methionine mutation at a site corresponding to R465 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a leucine to glutamine mutation at a site corresponding to L396 of SEQ ID NO: 2, and may further comprise a mutation at a site corresponding to V401, N424, P569, E617, or V640 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a serine to asparagine mutation at a site corresponding to S651 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a leucine to proline mutation at a site corresponding to L396 of SEQ ID NO: 2, and may further comprise a mutation at a site corresponding to E459 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a leucine to proline mutation at a site corresponding to L456 of SEQ ID NO: 2, and may further comprise a mutation at a site corresponding to E658 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprises a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2, and may further comprise a mutation at a site corresponding to V437, or L478 of SEQ ID NO: 2. The L408H mutation was isolated both in the dideoxynucleotide and the dye-dideoxynucleotide screens described herein.

In another embodiment, the Family B DNA polymerase comprises an tyrosine to asparagine mutation at a site corresponding to Y496 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides and conjugated nucleotides.

In another embodiment, the conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

In another embodiment, an isolated recombinant DNA polymerase having reduced discrimination against non-conventional nucleotides or an isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 of SEQ ID NO: 2, wherein the DNA polymerase has reduced discrimination against non-conventional nucleotides relative to the wild-type form of that polymerase further comprises a mutation at an amino acid residue in the polymerase that corresponds to a mutation selected from the group consisting of: a Y to V mutation at amino acid 409 of SEQ ID NO:2; an A to C, S, L, I, F, or V mutation at amino acid 485 of SEQ ID NO: 2; a Y to S mutation at amino acid 494 of SEQ ID NO: 2; a Y to L mutation

at amino acid 496 of SEQ ID NO: 2; and an A to Y mutation at amino acid 490 of SEQ ID NO: 2.

In another embodiment, an isolated recombinant DNA polymerase having reduced discrimination against non-conventional nucleotides or an isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 of SEQ ID NO: 2, wherein the DNA polymerase has reduced discrimination against non-conventional nucleotides relative to the wild-type form of that polymerase further comprises a mutation at an amino acid of the polymerase corresponding to one of amino acids 483 to 496, inclusive, of SEQ ID NO: 2.

In one embodiment, the mutation is at an amino acid of the polymerase corresponding to one of amino acids 485, 490, 494, or 496 of SEQ ID NO: 2.

The invention further encompasses an isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at an amino acid corresponding to A485T of SEQ ID NO: 2 and at least one substitution in the polymerase of an amino acid corresponding to L408, Y409, or P410, respectively, of SEQ ID NO: 2.

The invention further encompasses an isolated recombinant Family B DNA polymerase comprising an amino acid other than A at an amino acid of the polymerase corresponding to A485 of SEQ ID NO: 2, and at least one substitution in the polymerase of an amino acid corresponding to L408, Y409, or P410, respectively, of SEQ ID NO: 2.

The invention further encompasses a recombinant vector comprising a nucleic acid sequence encoding the Family B DNA polymerase.

The invention further encompasses a method of labeling a complementary strand of DNA, the method comprising the step of contacting a template DNA molecule with a recombinant Family B DNA polymerase from *Thermococcus* species JDF-3, wherein the DNA

polymerase has reduced discrimination against non-conventional nucleotides, and a non-conventional nucleotide, under conditions and for a time sufficient to permit the DNA polymerase to synthesize a complementary DNA strand and to incorporate the non-conventional nucleotide into the synthesized complementary DNA strand.

The invention further encompasses a method of labeling a complementary strand of DNA, the method comprising the step of contacting a template DNA molecule with a recombinant Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 of SEQ ID NO: 2, wherein the DNA polymerase has reduced discrimination against non-conventional nucleotides, and a non-conventional nucleotide, under conditions and for a time sufficient to permit the DNA polymerase to synthesize a complementary DNA strand and to incorporate the non-conventional nucleotide into the synthesized complementary DNA strand.

In one embodiment, the recombinant Family B DNA polymerase is 3' to 5' exonuclease deficient.

In another embodiment, the recombinant Family B polymerase comprises a leucine to histidine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprises a leucine to phenylalanine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprises a proline to leucine mutation at a site corresponding to amino acid P410 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprises an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprising an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 comprises a leucine to histidine mutation at an amino acid corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprising an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 comprises a leucine to phenylalanine mutation at an amino acid corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase comprising an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 comprises a proline to leucine mutation at an amino acid corresponding to P410 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides, and conjugated nucleotides.

In another embodiment, the conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

The invention further encompasses a method of sequencing DNA comprising the steps of contacting a DNA strand to be sequenced with a sequencing primer, a recombinant Family B DNA polymerase from *Thermococcus* species JDF-3, wherein the DNA polymerase has reduced discrimination against non-conventional nucleotides, and a chain-terminating nucleotide analog, under conditions that permit the DNA polymerase to synthesize a complementary DNA strand, and to incorporate nucleotides into the synthesized complementary DNA strand, wherein incorporation of a chain-terminating nucleotide analog results in the termination of chain elongation, such that the nucleotide sequence of the template DNA strand is determined.

The invention further encompasses a method of sequencing DNA comprising the steps of contacting a DNA strand to be sequenced with a sequencing primer, a recombinant Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408, S345 or P410 of SEQ ID NO: 2, where the DNA polymerase has reduced discrimination against non-conventional nucleotides, and a chain-terminating nucleotide analog, under conditions that permit the DNA polymerase to synthesize a complementary DNA strand, and to incorporate nucleotides into the synthesized complementary DNA strand, wherein incorporation of a chain-terminating nucleotide analog results in the termination of chain elongation, such that the nucleotide sequence of the template DNA strand is determined.

In one embodiment, the recombinant DNA polymerase is deficient in 3' to 5' exonuclease activity.

In another embodiment, the recombinant Family B polymerase has a leucine to histidine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase has a leucine to phenylalanine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase has a proline to leucine mutation at a site corresponding to amino acid P410 of SEQ ID NO: 2.

In another embodiment, the Family B DNA polymerase comprising a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2, further having a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase has an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase having an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 has a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase having an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 has a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

In another embodiment, the recombinant Family B polymerase having an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2 has a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

In another embodiment, the chain-terminating nucleotide analog is a dideoxynucleotide.

In another embodiment, the dideoxynucleotide is detectably labeled.

In another embodiment, the dideoxynucleotide is fluorescently labeled.

In another embodiment, the dideoxynucleotide is labeled with a moiety selected from the group consisting of fluorescein and rhodamine.

The invention also encompasses a kit for performing the methods disclosed herein.

The invention also encompasses methods of making a recombinant DNA polymerase as disclosed here, comprising culturing a host cell containing a nucleic acid sequence encoding said polymerase under conditions which permit production of said DNA polymerase.

The invention encompasses a mixture of a mutant DNA polymerase described herein and another DNA polymerase such as Taq DNA polymerase (preferably the mutant form, F667Y). Such a mixture is useful in that it may increase signal uniformity generated from polymerization of a labeled nucleotide into a synthetic nucleotide.

As used herein, "discrimination" refers to the tendency of DNA polymerase to not incorporate non-conventional nucleotides into a nascent DNA polymer. DNA polymerase has

the ability to sense nucleotide structure, including but not limited to nucleotide base complementarity, and structural features of the sugar and heterocyclic base, thereby allowing DNA polymerase to preferentially utilize conventional deoxynucleotides rather than non-conventional nucleotides for incorporation into a nascent polymer. DNA polymerase strongly prefers to incorporate the conventional deoxynucleotides dATP, dCTP, dGTP and TTP into DNA polymers; the polymerase is unlikely to progress with an unconventional nucleotide in its binding pocket.

As used herein, “reduced discrimination” refers to a reduction of at least 50% in the tendency of a DNA polymerase to exclude a non-conventional nucleotide from (that is, to not incorporate non-conventional nucleotides into) a nascent DNA polymer, relative to a parental or wild type DNA polymerase which does not exhibit reduced discrimination. The preference of DNA polymerase to incorporate the conventional deoxynucleotides dATP, dCTP, dGTP and TTP rather than non-conventional nucleotides into DNA polymers is thereby reduced compared to the natural level of preference, such that non-conventional nucleotides are more readily incorporated into DNA polymers by DNA polymerase. According to the invention, a polymerase exhibiting reduced discrimination will exhibit reduced discrimination against at least one non-conventional nucleotides, but may not exhibit reduced discrimination against all non-conventional nucleotides.

According to the invention, discrimination is quantitated by measuring the concentration of a non-conventional nucleotide required to inhibit the incorporation of the corresponding conventional nucleotide by 50%. This concentration is referred to herein as the “ $I_{50\%}$ ” for a non-conventional nucleotide. Discrimination against a given non-conventional nucleotide is “reduced” if the $I_{50\%}$ for that non-conventional nucleotide is reduced by at least two fold (50%)

relative to an identical assay containing, in place of the mutant DNA polymerase, a parental DNA polymerase.

Alternatively, reduced discrimination may be quantitated by determining the amount of a non-conventional nucleotide (for example, a dideoxynucleotide, ribonucleotide, or cordycepin) required in a reaction with a mutant polymerase having reduced discrimination to generate a sequencing ladder identical to a sequencing ladder produced using the wild-type or parental enzyme. The sequencing ladder can be examined, for example, in the range of 1 to 400 bases from the primer terminus, and the ladders will be identical in the number of extension products generated as well as the lengths of extension products generated in the sequencing reaction. For this type of assay, a constant amount of dNTPs and varying amounts of non-conventional nucleotides are used to generate a sequencing ladder with both the wild-type (or parental) enzyme and the mutant polymerase (for ribonucleotides, a sequencing ladder is generated by alkali cleavage of the polymerization products). See Gardner & Jack, 1999, *supra*. A mutant exhibits reduced discrimination if it requires at least two-fold (50%) less, five-fold (80%) less, ten-fold (100%) less, etc. of the amount of the non-conventional nucleotide used by the wild-type or parental polymerase to produce a sequencing ladder identical (with respect to the number and length of extension products generated) to that generated by the wild-type or parental enzyme.

As used herein, the term “parental” or “progenitor” refers to a polymerase used as the starting material in generating a mutant polymerase having reduced discrimination. The term “parental” is meant to encompass not only a so-called “wild-type” enzyme as it occurs in nature, but also intermediate forms, for example, an exonuclease deficient enzyme that is used as the starting material for generating an enzyme with reduced discrimination against non-conventional nucleotides.

As used herein, “non-conventional nucleotide” refers to a) a nucleotide structure that is not one of the four conventional deoxynucleotides dATP, dCTP, dGTP, and TTP recognized by and incorporated by a DNA polymerase, b) a synthetic nucleotide that is not one of the four conventional deoxynucleotides in (a), c) a modified conventional nucleotide, or d) a ribonucleotide (since they are not normally recognized or incorporated by DNA polymerases) and modified forms of a ribonucleotide. Non-conventional nucleotides include but are not limited to those listed in Table III, which are commercially available, for example, from New England Nuclear. Any one of the above non-conventional nucleotides may be a “conjugated nucleotide”, which as used herein refers to nucleotides bearing a detectable label, including but not limited to a fluorescent label, isotope, chemiluminescent label, quantum dot label, antigen, or affinity moiety.

As used herein, the term “cell”, “cell line” and “cell culture” can be used interchangeably and all such designations include progeny. Thus, the words “transformants” or “transformed cells” includes the primary subject cell and cultures derived therefrom without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Mutant progeny that have the same functionality as screened for in the originally transformed cell are included.

As used herein, the term “organism transformed with a vector” refers to an organism carrying a recombinant gene construct.

As used herein, “thermostable” refers to a property of a DNA polymerase, such that the enzyme active at elevated temperatures and is resistant to DNA duplex-denaturing temperatures in the range of about 93°C to about 97 °C. “Active” means the enzyme retains the ability to effect primer extension reactions when subjected to elevated or denaturing temperatures for the time necessary to effect denaturation of double-stranded nucleic acids. Elevated temperatures as

used herein refer to the range of about 70°C to about 75 °C, whereas non-elevated temperatures as used herein refer to the range of about 35°C to about 50 °C.

As used herein, “archaeal” refers to an organism or to a DNA polymerase from an organism of the kingdom Archaea.

As used herein, “sequencing primer” refers to an oligonucleotide, whether natural or synthetic, which serves as a point of initiation of nucleic acid synthesis by a polymerase following annealing to a DNA strand to be sequenced. A primer is typically a single-stranded oligodeoxyribonucleotide. The appropriate length of a primer depends on the intended use of the primer, but for DNA sequencing applications typically ranges from about 15 to about 40 nucleotides in length.

As used herein, “Family B DNA polymerase” refers to any DNA polymerase that is classified as a member of the Family B DNA polymerases, where the Family B classification is based on structural similarity to *E. coli* DNA polymerase II. The Family B DNA polymerases, formerly known as α -family polymerases, include, but are not limited to those listed as such in Table I.

As used herein, “Family A DNA polymerase” refers to any DNA polymerase that is classified as a member of the Family A DNA polymerases, where the Family A classification is based on structural similarity to *E. coli* DNA polymerase I. Family A DNA polymerases include, but are not limited to those listed as such in Table I.

As used herein, “3’ to 5’ exonuclease deficient” or “3’ to 5’ exo^- ” refers to an enzyme that substantially lacks the ability to remove incorporated nucleotides from the 3’ end of a DNA polymer. DNA polymerase exonuclease activities, such as the 3’ to 5’ exonuclease activity exemplified by members of the Family B polymerases, can be lost through mutation, yielding an exonuclease-deficient polymerase. As used herein, a DNA polymerase that is deficient in 3’ to

5' exonuclease activity substantially lacks 3' to 5' exonuclease activity. "Substantially lacks" encompasses a complete lack of activity, or a "substantial" lack of activity. "Substantial" lack of activity means that the 3' exonuclease activity of the mutant polymerase relative to the parental polymerase is 0.03%, and also may be 0.05%, 0.1%, 1%, 5%, 10%, or 20%, but is not higher than 50% of the 3' exonuclease activity of the parental or wild type polymerase.

As used herein, "mutation" refers to a change introduced into a starting parental DNA sequence that changes the amino acid sequence encoded by the DNA. The consequences of a mutation include but are not limited to the creation of a new character, property, function, or trait not found in the protein encoded by the parental DNA.

As used herein, "wild-type" refers to the typical state of an organism, strain, gene, protein or characteristic as it occurs in nature. The wild-type is therefore the natural state that is distinguished from a mutant, which was derived from the wild type by introduction of change(s) to the wild-type.

As used herein, "corresponding" refers to sequence similarity in a comparison of two or more nucleic acids or polypeptides, where functionally equivalent domains or sub-sequences are identified; such functionally equivalent domains or sub-sequences or amino acids within such a domain or sub-sequence are said to "correspond". That is, two or more sequences are compared through a comparative alignment analysis in which an entire sequence is examined for regions of sequence that are similar or identical, and thus regions likely to be functionally equivalent to regions from the other sequence(s) are identified.

As used herein in reference to comparisons of an amino acid, amino acid sequence, or protein domain, the term "similar" refers to amino acids or domains that although not identical, represent "conservative" differences. By "conservative" is meant that the differing amino acid has like characteristics with the amino acid in the corresponding or reference sequence. Typical

conservative substitutions are among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. In calculating the degree (most often as a percentage) of similarity between two polypeptide sequences, one considers the number of positions at which identity or similarity is observed between corresponding amino acid residues in the two polypeptide sequences in relation to the entire lengths of the two molecules being compared.

As used herein, the term “functionally equivalent” means that a given motif, region, or amino acid within a motif or region performs the same function with regard to the overall function of the enzyme as a motif, region or amino acid within a motif or region performs in another enzyme.

As used herein, “chain terminating nucleotide analog” refers to a nucleotide analog that once incorporated cannot serve as a substrate for subsequent extension by a DNA polymerase, thereby terminating the elongation of a DNA polymer by a DNA polymerase. Such a nucleotide analog typically lacks a hydroxyl group on its sugar moiety to which DNA polymerase can synthesize a phosphodiester bond with an incoming nucleotide. Chain terminating nucleotide analogs are a subset of non-conventional nucleotides, and include but are not limited to dideoxynucleotides.

As used herein, “detectably labeled” refers to a structural modification that incorporates a functional group (label) that can be readily detected by various means. Compounds that can be detectably labeled include but are not limited to nucleotide analogs. Detectable nucleotide analog labels include but are not limited to fluorescent compounds, isotopic compounds, chemiluminescent compound, quantum dot labels, biotin, enzymes, electron-dense reagents, and haptens or proteins for which antisera or monoclonal antibodies are available. The various

means of detection include but are not limited to spectroscopic, photochemical, biochemical, immunochemical, or chemical means.

As used herein in reference to a polynucleotide or polypeptide, the term “isolated” means that a naturally occurring sequence has been removed from its normal cellular environment or is synthesized in a non-natural environment (*e.g.*, artificially synthesized). Thus, the sequence may be in a cell-free solution or placed in a different cellular environment. The term does not imply that the sequence is the only nucleotide or polypeptide chain present, but that it is essentially free (about 90-95% pure at least) of non-nucleotide or non-polypeptide material, respectively, naturally associated with it.

As used herein, the term “recombinant” refers to a polynucleotide or polypeptide that is altered by genetic engineering (*i.e.*, by modification or manipulation of the genetic material encoding that polynucleotide or polypeptide).

The invention encompasses full length mutant DNA polymerases, as described herein, as well as a functional fragment of a mutant polymerase, that is, a fragment of a DNA polymerase that is less than the entire amino acid sequence of the mutant polymerase and retains the ability, under at least one set of conditions, to catalyze the polymerization of a polynucleotide. Such a functional fragment may exist as a separate entity, or it may be a constituent of a larger polypeptide, such as a fusion protein.

As used herein, the term “complementary DNA strand” refers to that DNA molecule synthesized from a template DNA molecule by a DNA polymerase in a primer extension reaction.

As used herein, the term “template DNA molecule” refers to that strand of a nucleic acid from which a complementary nucleic acid strand is synthesized by a DNA polymerase, for example, in a primer extension reaction.

Further features and advantages of the invention will become more fully apparent in the following description of the embodiments and drawings thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the DNA sequence encoding *Thermococcus species* JDF-3 DNA polymerase (intein removed) (SEQ ID NO: 1).

Figure 2 shows the amino sequence of *Thermococcus species* JDF-3 DNA polymerase (intein removed) (SEQ ID NO: 2).

Figure 3 shows the amino acid sequence of the genomic clone encoding *Thermococcus species* JDF-3 DNA polymerase (SEQ ID NO: 3). The position of an intein, removed by post-translational processing, is shown.

Figure 4 shows the DNA sequence of the genomic clone encoding *Thermococcus species* JDF-3 DNA polymerase (SEQ ID NO: 4). DNA sequences are shown which correspond to 5' and 3' untranslated regions, polymerase-coding regions (exteins), and an intein-coding region.

Figure 5 shows nucleotide incorporation by JDF-3 mutants. Lambda phage clones which incorporated ³³P-labeled ddNTPs in the primary library screen were rescreened to assess ³³P-ddNTP incorporation in the presence of: (panel 1) 0.5mM MnCl₂ or (panel 2) 1.5mM MgCl₂. Polymerase activity was measured using ³³P-dNTPs in the presence of 1.5mM MgCl₂ (panel 3). Nucleotide utilization is shown for clones 1-18 and for the parental #550 clone.

Figure 6 shows ³³P-ddNTP cycle sequencing reactions performed using JDF-3 polymerase mutants. Purified JDF-3 mutants were substituted into the Thermo Sequenase radiolabeled terminator cycle sequencing kit. DNA sequencing ladders were generated as per the kit's instructions using the following polymerases: (A) Thermo Sequenase (B) JDF-3 #550 clone (parental) (C) JDF-3 A485T mutant (clone p12) (D) JDF-3 P410L mutant (clone p11) (E) JDF-3 P410L mutant (clone p8). The top of the original sequencing gel is shown on the side. The lanes

are: (bottom) ddGTP, ddATP, ddTTP, ddCTP (top). Clones p8, p11, and p12 contain ancillary mutations and an amino-terminal tag.

Figure 7 shows cycle sequencing reactions performed using dye-labeled ddNTPs and JDF-3 polymerase mutants. DNA sequencing ladders were generated using (1) 2.14 μ M dNTP: 0.0214 μ M ddNTP; (2) 2.14 μ M dNTP: 0.214 μ M ddNTP; or (3) 2.14 μ M dNTP: 2.14 μ M ddNTP. The following purified DNA polymerases were used: (A) JDF-3 #550 clone (parental) (B) Thermo Sequenase (C) JDF-3 P410L mutant (clone p8, contains ancillary mutations and an amino tag) (E) JDF-3 L408H mutant (clone 1-1). The top of the original sequencing gel is shown on the right hand side.

Figure 8 shows cycle sequencing reactions performed using the JDF-3 P410L/A485T double mutant and α -³³P Dideoxynucleotides. DNA sequencing ladders were generated using the JDF-3 P410L/A485T double mutant at (A) 2 μ l (B) 1 μ l (C) 0.5 μ l, the JDF-3 P410L mutant (clone p8, contains ancillary mutations and an amino-terminal tag)(D), or Thermo Sequenase (E). The top of the original sequencing gel is shown on the left side. The lanes are: (bottom) ddGTP, ddATP, ddTTP, ddCTP (top).

Figure 9 shows the result of ribonucleotide incorporation assays using exo JDF-3 (550) and mutants of this progenitor clone. The ratios of ribonucleotide versus deoxynucleotide incorporation are plotted for JDF-3 550, JDF-3 L408H, JDF-3 L408F and JDF-3 A485T.

Figure 10 shows the traces of the sequence generated by four versions of JDF-3 DNA polymerase and FAM ddCTP. Panel A shows the minimal trace produced by the progenitor polymerase JDF-3 550, Panel B demonstrates the slightly improved trace made by JDF-3 P410L, Panel C shows the sequence generated by the double mutant S345P and P410L, and Panel D shows the trace created by JDF-3 S345P.

Figure 11 shows the difference in peak uniformity demonstrated by Thermo Sequenase in Panel A and the double mutant JDF-3 S345P + P410L in Panel B.

Figure 12 shows the separated products of 3' extension of a labeled oligonucleotide with the dideoxynucleotide thymidine triphosphate of ROX-ddUTP (New England Nuclear (NEN) NEL476) or Fluorescein-12-ddUTP (NEN NEL401). Mutant 4 is JDF-3 S345P, Mutant 2 is JDF-3 P410L, Mutant 3 is JDF-3 A485T and Mutant 5 is Y496N. F indicates FLU ddUTP and R indicates ROX ddUTP.

Figure 13 shows a graphic representation of the relative band intensities from Figure 12. The numerical values are generated by dividing the intensity value of the ddTTP band into the intensity value for the Fluorescein-12-ddUTP bands.

Figure 14 shows the sequence alignment of dye-dideoxynucleotide selected JDF-3 mutants (amino acids 301-480). Nucleic acid residues highlighted by white boxes indicate the location of a mutation. The mutation S345P is one of two mutations present in mutant 28.

Figure 15 shows the sequence alignment of dye-dideoxynucleotide selected JDF-3 (amino acids 481-660). Nucleic acid residues highlighted by white boxes indicate the location of a mutation.

DESCRIPTION

The invention is based on the discovery of Family B DNA polymerases that bear one or more genetic alterations resulting in reduced discrimination against non-conventional nucleotides relative to their unmodified wild-type forms. All references described herein are incorporated by reference herein in their entirety.

Family B DNA Polymerase Exhibiting Reduced Discrimination Against Non-Conventional Nucleotides:

A. DNA Polymerases Useful According to the Invention

According to the invention, DNA polymerases of Family B may be mutated to generate enzymes exhibiting reduced discrimination against non-conventional nucleotides.

Table I includes a non-limiting list of known DNA polymerases categorized by family.

Table I. DNA POLYMERASES BY FAMILY
FAMILY A DNA POLYMERASES

Bacterial DNA Polymerases	Reference
a) <i>E. coli</i> DNA polymerase I	(1)
b) <i>Streptococcus pneumoniae</i> DNA polymerase I	(2)
c) <i>Thermus aquaticus</i> DNA polymerase I	(3)
d) <i>Thermus flavus</i> DNA polymerase I	(4)
e) <i>Thermotoga maritima</i> DNA polymerase I	
Bacteriophage DNA Polymerases	
a) T5 DNA polymerase	(5)
b) T7 DNA polymerase	(6)
c) Spo1 DNA polymerase	(7)
d) Spo2 DNA polymerase	(8)

Mitochondrial DNA polymerase	
Yeast Mitochondrial DNA polymerase II	(9, 10, 11)

FAMILY B DNA POLYMERASES

Bacterial DNA polymerase	
<i>E. coli</i> DNA polymerase II	(15)
Bacteriophage DNA polymerase	
a) PRD1 DNA polymerase	(16, 17)
b) ϕ 29 DNA polymerase	(18)
c) M2 DNA polymerase	(19)
d) T4 DNA polymerase	(20)
Archaeal DNA polymerase	
a) Thermococcus litoralis DNA polymerase (Vent)	(21)
b) Pyrococcus furiosus DNA polymerase	(22)
c) Sulfolobus solfataricus DNA polymerase	(23)
d) Thermococcus gorgonarius DNA polymerase	(64)
e) Thermococcus species TY	(65)
f) Pyrococcus species strain KOD1	(66)
g) Sulfolobus acidocaldarius	(67)
h) Thermococcus species 9 ^o N-7	(68)
i) Pyrodictium occultum	(69)
j) Methanococcus voltae	(70)
k) Desulfurococcus strain TOK (D. Tok Pol)	(71)
Eukaryotic Cell DNA polymerase	
(1) DNA polymerase alpha	
a) Human DNA polymerase (alpha)	(24)
b) S.cerevisiae DNA polymerase (alpha)	(25)

c) *S.pombe* DNA polymerase I (alpha) (26)

d) *Drosophila melanogaster* DNA polymerase (alpha) (27)

e) *Trypanosoma brucei* DNA polymerase (alpha) (28)

(2) DNA polymerase delta

a) Human DNA polymerase (delta) (29, 30)

b) Bovine DNA polymerase (delta) (31)

c) *S. cerevisiae* DNA polymerase III (delta) (32)

d) *S. pombe* DNA polymerase III (delta) (33)

e) *Plasmodium falciparum* DNA polymerase (delta) (34)

(3) DNA polymerase epsilon

S. cerevisiae DNA polymerase II (epsilon) (35)

(4) Other eukaryotic DNA polymerase

S. cerevisiae DNA polymerase Rev3 (36)

Viral DNA polymerases

a) Herpes Simplex virus type 1 DNA polymerase (37)

b) Equine herpes virus type 1 DNA polymerase (38)

c) Varicella-Zoster virus DNA polymerase (39)

d) Epstein-Barr virus DNA polymerase (40)

e) Herpesvirus saimiri DNA polymerase (41)

f) Human cytomegalovirus DNA polymerase (42)

g) Murine cytomegalovirus DNA polymerase (43)

h) Human herpes virus type 6 DNA polymerase (44)

i) Channel Catfish virus DNA polymerase (45)

j) *Chlorella* virus DNA polymerase (46)

k) Fowlpox virus DNA polymerase	(47)
l) Vaccinia virus DNA polymerase	(48)
m) Choristoneura biennis DNA polymerase	(49)
n) Autographa californica nuclear polymerase virus (AcMNPV)	
DNA polymerase	(50)
o) Lymantria dispar nuclear polyhedrosis virus DNA polymerase	(51)
p) Adenovirus-2 DNA polymerase	(52)
q) Adenovirus-7 DNA polymerase	(53)
r) Adenovirus-12 DNA polymerase	(54)

Eukaryotic linear DNA plasmid encoded DNA polymerases

a) S-1 Maize DNA polymerase	(55)
b) kalilo neurospora intermedia DNA polymerase	(56)
c) pA12 ascobolus immersus DNA polymerase	(57)
d) pCLK1 Claviceps purpurea DNA polymerase	(58)
e) maranhar neurospora crassa DNA polymerase	(59)
f) pEM Agaricus bitorquis DNA polymerase	(60)
g) pGKL1 Kluyveromyces lactis DNA polymerase	(61)
h) pGKL2 Kluyveromyces lactis DNA polymerase	(62)
i) pSKL Saccharomyces kluyveri DNA polymerase	(63)

B. Plasmids

The starting sequences for the generation of Family B DNA polymerases according to the invention may be contained in a plasmid vector. A non-limiting list of cloned Family B DNA polymerases and their GenBank Accession numbers are listed in Table II.

Table II. Accession Information for Cloned Family B Polymerases

Vent Thermococcus litoralis

ACCESSION AAA72101

PID g348689

VERSION AAA72101.1 GI:348689

DBSOURCE locus THCVDPE accession M74198.1

THEST THERMOCOCCUS SP. (STRAIN TY)

ACCESSION O33845

PID g3913524

VERSION O33845 GI:3913524

DBSOURCE swissprot: locus DPOL_THEST, accession O33845

Pab Pyrococcus abyssi

ACCESSION P77916

PID g3913529

VERSION P77916 GI:3913529

DBSOURCE swissprot: locus DPOL_PYRAB, accession P77916

PYRHO Pyrococcus horikoshii

ACCESSION O59610

PID g3913526

VERSION O59610 GI:3913526

DBSOURCE swissprot: locus DPOL_PYRHO, accession O59610

PYRSE PYROCOCCUS SP. (STRAIN GE23)

ACCESSION P77932

PID g3913530

VERSION P77932 GI:3913530

DBSOURCE swissprot: locus DPOL_PYRSE, accession P77932

DeepVent Pyrococcus sp.

ACCESSION AAA67131

PID g436495

VERSION AAA67131.1 GI:436495

DBSOURCE locus PSU00707 accession U00707.1

Pfu Pyrococcus furiosus

ACCESSION P80061

PID g399403

VERSION P80061 GI:399403

DBSOURCE swissprot: locus DPOL_PYRFU, accession P80061

JDF-3 Thermococcus sp.

Unpublished

Baross gi|2097756|pat|US|5602011|12 Sequence 12 from patent US 5602011

9degN THERMOCOCCUS SP. (STRAIN 9ON-7).
ACCESSION Q56366
PID g3913540
VERSION Q56366 GI:3913540
DBSOURCE swissprot: locus DPOL_THES9, accession Q56366

KOD Pyrococcus sp.
ACCESSION BAA06142
PID g1620911
VERSION BAA06142.1 GI:1620911
DBSOURCE locus PYWKODPOL accession D29671.1

Tgo Thermococcus gorgonarius.
ACCESSION 4699806
PID g4699806
VERSION GI:4699806
DBSOURCE pdb: chain 65, release Feb 23, 1999

THEFM Thermococcus fumicolans
ACCESSION P74918
PID g3913528
VERSION P74918 GI:3913528
DBSOURCE swissprot: locus DPOL_THEFM, accession P74918

METTH Methanobacterium thermoautotrophicum
ACCESSION O27276
PID g3913522
VERSION O27276 GI:3913522
DBSOURCE swissprot: locus DPOL_METTH, accession O27276

Metja Methanococcus jannaschii
ACCESSION Q58295
PID g3915679
VERSION Q58295 GI:3915679
DBSOURCE swissprot: locus DPOL_METJA, accession Q58295

POC Pyrodictium occultum
ACCESSION B56277
PID g1363344
VERSION B56277 GI:1363344
DBSOURCE pir: locus B56277

Apel Aeropyrum pernix
ACCESSION BAA81109
PID g5105797
VERSION BAA81109.1 GI:5105797
DBSOURCE locus AP000063 accession AP000063.1

ARCFU Archaeoglobus fulgidus
ACCESSION O29753
PID g3122019
VERSION O29753 GI:3122019
DBSOURCE swissprot: locus DPOL_ARCFU, accession O29753

Desulfurococcus sp. Tok.
ACCESSION 6435708
PID g64357089
VERSION GT:6435708
DBSOURCE pdb. chain 65, release Jun 2, 1999

Plasmids acceptable for the expression of modified forms of Family B DNA polymerases may be selected from a large number known in the art by one of skill in the art. A plasmid vector for expression of a modified DNA polymerase according to the invention will preferably comprise sequences directing high level expression of a DNA polymerase, and will more preferably comprise sequences directing inducible, high level expression of a DNA polymerase. As one example of an inducible high level expression system, plasmids placing a modified DNA polymerase coding sequence according to the invention under the control of a bacteriophage T7 promoter may be introduced to bacteria containing an inducible T7 RNA polymerase gene within their chromosome. Induction of the T7 RNA polymerase gene subsequently induces high level expression of the T7 promoter-driven modified DNA polymerase gene (see for example, Gardner & Jack, Nucleic Acids Res. 27: 2545).

C. Mutagenesis

The cloned wild-type form of a Family B DNA polymerase may be mutated to generate forms exhibiting reduced discrimination against non-conventional nucleotides by a number of methods.

First, methods of random mutagenesis which will result in a panel of mutants bearing one or more randomly-situated mutations exist in the art. Such a panel of mutants may then be screened for those exhibiting reduced discrimination relative to the wild-type polymerase (see

“Methods of Evaluating Mutants for Reduced Discrimination”, below). An example of a method for random mutagenesis is the so-called “error-prone PCR method”. As the name implies, the method amplifies a given sequence under conditions in which the DNA polymerase does not support high fidelity incorporation. The conditions encouraging error-prone incorporation for different DNA polymerases vary, however one skilled in the art may determine such conditions for a given enzyme. A key variable for many DNA polymerases in the fidelity of amplification is, for example, the type and concentration of divalent metal ion in the buffer. The use of manganese ion and/or variation of the magnesium or manganese ion concentration may therefore be applied to influence the error rate of the polymerase.

Second, there are a number of site-directed mutagenesis methods known in the art which allow one to mutate a particular site or region in a straightforward manner. There are a number of kits available commercially for the performance of site-directed mutagenesis, including both conventional and PCR-based methods. Examples include the EXSITE™ PCR-Based Site-directed Mutagenesis Kit available from Stratagene (Catalog No. 200502; PCR based) and the QUIKCHANGE™ Site-directed mutagenesis Kit from Stratagene (Catalog No. 200518; non-PCR-based), and the CHAMELEON® double-stranded Site-directed mutagenesis kit, also from Stratagene (Catalog No. 200509).

Older methods of site-directed mutagenesis known in the art relied upon sub-cloning of the sequence to be mutated into a vector, such as an M13 bacteriophage vector, that allows the isolation of single-stranded DNA template. In these methods one annealed a mutagenic primer (i.e., a primer capable of annealing to the site to be mutated but bearing one or mismatched nucleotides at the site to be mutated) to the single-stranded template and then polymerized the complement of the template starting from the 3' end of the mutagenic primer. The resulting

duplexes were then transformed into host bacteria and plaques were screened for the desired mutation.

More recently, site-directed mutagenesis has employed PCR methodologies, which have the advantage of not requiring a single-stranded template. In addition, methods have been developed that do not require sub-cloning. Several issues must be considered when PCR-based site-directed mutagenesis is performed. First, in these methods it is desirable to reduce the number of PCR cycles to prevent expansion of undesired mutations introduced by the polymerase. Second, a selection must be employed in order to reduce the number of non-mutated parental molecules persisting in the reaction. Third, an extended-length PCR method is preferred in order to allow the use of a single PCR primer set. And fourth, because of the non-template-dependent terminal extension activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to blunt-end ligation of the PCR-generated mutant product.

The protocol described below accommodates these considerations through the following steps. First, the template concentration used is approximately 1000-fold higher than that used in conventional PCR reactions, allowing a reduction in the number of cycles from 25-30 down to 5-10 without dramatically reducing product yield. Second, the restriction endonuclease DpnI (recognition target sequence: 5-Gm6ATC-3, where the A residue is methylated) is used to select against parental DNA, since most common strains of *E. coli* Dam methylate their DNA at the sequence 5-GATC-3. Third, Taq Extender is used in the PCR mix in order to increase the proportion of long (i.e., full plasmid length) PCR products. Finally, Pfu DNA polymerase is used to polish the ends of the PCR product prior to intramolecular ligation using T4 DNA ligase. The method is described in detail as follows:

PCR-based Site Directed Mutagenesis of the 3'-5' Exonuclease domain

Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing: 1x mutagenesis buffer (20 mM Tris HCl, pH 7.5; 8 mM MgCl₂; 40 ug/ml BSA); 12-20 pmole of each primer (one of skill in the art may design a mutagenic primer as necessary, giving consideration to those factors such as base composition, primer length and intended buffer salt concentrations that affect the annealing characteristics of oligonucleotide primers; one primer must contain the desired mutation, and one (the same or the other) must contain a 5' phosphate to facilitate later ligation), 250 uM each dNTP, 2.5 U Taq DNA polymerase, and 2.5 U of Taq Extender (Available from Stratagene; See Nielson et al. (1994) Strategies 7: 27, and U.S. Patent No. 5,556,772). The PCR cycling is performed as follows: 1 cycle of 4 min at 94°C, 2 min at 50°C and 2 min at 72°C; followed by 5-10 cycles of 1 min at 94°C, 2 min at 54°C and 1 min at 72°C. The parental template DNA and the linear, PCR-generated DNA incorporating the mutagenic primer are treated with DpnI (10 U) and Pfu DNA polymerase (2.5U). This results in the DpnI digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the non-template-directed Taq DNA polymerase-extended base(s) on the linear PCR product. The reaction is incubated at 37°C for 30 min and then transferred to 72°C for an additional 30 min. Mutagenesis buffer (115 ul of 1x) containing 0.5 mM ATP is added to the DpnI-digested, Pfu DNA polymerase-polished PCR products. The solution is mixed and 10 ul are removed to a new microfuge tube and T4 DNA ligase (2-4 U) is added. The ligation is incubated for greater than 60 min at 37°C. Finally, the treated solution is transformed into competent *E. coli* according to standard methods.

D. Non-Conventional Nucleotides Useful According to the Invention.

There is a wide variety of non-conventional nucleotides available in the art. Any or all of them are contemplated for use with a DNA polymerase of the invention. A non-limiting list of such non-conventional nucleotides is presented in Table III.

**Table III. Non-Conventional Nucleotides
DIDEOXYNUCLEOTIDE ANALOGS**

Fluorescein Labeled	Fluorophore Labeled
Fluorescein-12-ddCTP	Eosin-6-ddCTP
Fluorescein-12-ddUTP	Coumarin-5-ddUTP
Fluorescein-12-ddATP	Tetramethylrhodamine-6-ddUTP
Fluorescein-12-ddGTP	Texas Red-5-ddATP
Fluorescein-N6-ddATP	LISSAMINE TM -rhodamine-5-ddGTP
FAM Labeled	TAMRA Labeled
FAM-ddUTP	TAMRA-ddUTP
FAM-ddCTP	TAMRA-ddCTP
FAM-ddATP	TAMRA-ddATP
FAM-ddGTP	TAMRA-ddGTP
ROX Labeled	JOE Labeled
ROX-ddUTP	JOE-ddUTP
ROX-ddCTP	JOE-ddCTP
ROX-ddATP	JOE-ddATP
ROX-ddGTP	JOE-ddGTP
R6G Labeled	R110 Labeled
R6G-ddUTP	R110-ddUTP
R6G-ddCTP	R110-ddCTP
R6G-ddATP	R110-ddATP
R6G-ddGTP	R110-ddGTP

BIOTIN Labeled

Biotin-N6-ATP

DNP Labeled

DNP-N6-ddATP

DEOXYNUCLEOTIDE ANALOGS**TTP Analogs**

Fluorescein-12-dUTP

Coumarin-5-dUTP

Tetramethylrhodamine-6-dUTP

Tetraethylrhodamine-6-dUTP

Texas Red-5-dUTP

LISSAMINETM-rhodamine-5-dUTP

Naphthofluorescein-5-dUTP

Fluorescein Chlorotriazinyl-4-dUTP

Pyrene-8-dUTP

Diethylaminocoumarin-5-dUTP

dATP-Analogs

Coumarin-5-dATP

Diethylaminocoumarin-5-dATP

Fluorescein-12-dATP

Fluorescein Chlorotriazinyl-4-dATP

LISSAMINETM-rhodamine-5-dATP

Naphthofluorescein-5-dATP

Pyrene-8-dATP

Tetramethylrhodamine-6-dATP

Texas Red-5-dATP

DNA-N6-dATP

Biotin-N6-dATP

dCTP Analogs

Coumarin-5-dCTP

Fluorescein-12-dCTP

Tetramethylrhodamine-6-dCTP

Texas Red-5-dCTP

LISSAMINETM-rhodamine-5-dCTP

Naphthofluorescein-5-dCTP

Fluorescein Chlorotriazinyl-4-dCTP

dGTP Analogs

Coumarin-5-dGTP

Fluorescein-12-dGTP

Tetramethylrhodamine-6-dGTP

Texas Red-5-dGTP

LISSAMINETM-rhodamine-5-dGTP

Pyrene-8-dCTP

Diethylaminocoumarin-5-dCTP

Fluorescein-N4-dCTP

Biotin-N4-dCTP

DNP-N4-dCTP

RIBONUCLEOTIDE ANALOGS

CTP Analogs

Coumarin-5-CTP

Fluorescein-12-CTP

Tetramethylrhodamine-6-CTP

Texas Red-5-CTP

LISSAMINETM-rhodamine-5-CTP

Naphthofluorescein-5-CTP

Fluorescein Chlorotriazinyl-4-CTP

Pyrene-8-CTP

Fluorescein-N4-CTP

Biotin-N4-CTP

ATP Analogs

Coumarin-5-ATP

Fluorescein-12-ATP

Tetramethylrhodamine-6-ATP

Texas Red-5-ATP

LISSAMINETM-rhodamine-5-ATP

Fluorescein-N6-ATP

UTP Analogs

Fluorescein-12-UTP

Coumarin-5-UTP

Tetramethylrhodamine-6-UTP

Texas Red-5-UTP

LISSAMINETM-5-UTP

Naphthofluorescein-5-UTP

Fluorescein Chlorotriazinyl-4-UTP

Pyrene-8-UTP

Biotin-N6-ATP

DNP-N6-ATP

Additional non-conventional nucleotides useful according to the invention include, but are not limited to 7-deaza-dATP, 7-deaza-dGTP, 5'-methyl-2'-deoxycytidine-5'-triphosphate. Further non-conventional nucleotides or variations on those listed above are discussed by Wright & Brown, 1990, Pharmacol. Ther. 47: 447. It is specifically noted that ribonucleotides qualify as non-conventional nucleotides, since ribonucleotides are not generally incorporated by DNA polymerases. Modifications of Family B DNA polymerases that result in the ability, or enhanced ability, of the polymerase to incorporate labeled or unlabeled ribonucleotides are specifically contemplated herein.

E. Methods of Evaluating Mutants for Reduced Discrimination

Random or site-directed mutants generated as known in the art or as described herein and expressed in bacteria may be screened for reduced discrimination against non-conventional nucleotides by several different assays. In one method, Family B DNA polymerase proteins expressed in lytic lambda phage plaques generated by infection of host bacteria with expression vectors based on, for example, Lambda ZapII®, are transferred to a membrane support. The immobilized proteins are then assayed for polymerase activity on the membrane by immersing the membranes in a buffer containing a DNA template and the unconventional nucleotides to be monitored for incorporation.

Mutant polymerase libraries may be screened using a variation of the technique used by Sagner *et al* (Sagner, G., Ruger, R., and Kessler, C. (1991) *Gene* 97:119-123). For this approach, lambda phage clones are plated at a density of 10-20 plaques per square centimeter. Proteins present in the plaques are transferred to filters and moistened with polymerase screening

buffer (50mM Tris (pH 8.0), 7mM MgCl₂, 3mM β-ME). The filters are kept between layers of plastic wrap and glass while the host cell proteins are heat-inactivated by incubation at 65°C for 30 minutes. The heat-treated filters are then transferred to fresh plastic wrap and approximately 35μl of polymerase assay cocktail are added for every square centimeter of filter. The assay cocktail consists of 1X cloned Pfu (cPfu) magnesium free buffer (1X buffer is 20 mM Tris-HCl (pH 8.8), 10 mM KCl, 10 mM (NH₄)₂SO₄, 100 ug/ml bovine serum albumin (BSA), and 0.1% Triton X-100; Pfu Magnesium-free buffer may be obtained from Stratagene (Catalog No. 200534)), 125 ng/ml activated calf thymus or salmon sperm DNA, 1.29 μCi/ml α-³³P ddNTP or dideoxynucleotides (at a dNTP:dye-ddNTP ratio of 1:15). Initial screening was done in the presence of MnCl₂, but the preferred method was to screen in 1X Taq Polymerase buffer (1.5 mM MgCl₂) The filters are placed between plastic wrap and a glass plate and then incubated at 65°C for one hour, and then at 70°C for one hour and fifteen minutes. Filters are then washed three times in 2X SSC for five minutes per wash before rinsing twice in 100% ethanol and vacuum drying. Filters are then exposed to X-ray film (approximately 16 hours), and plaques that incorporate label are identified by aligning the filters with the original plate bearing the phage clones. Plaques identified in this way are re-plated at more dilute concentrations and assayed under similar conditions to allow the isolation of purified plaques.

In assays such as the one described above, the signal generated by the label is a direct measure of the activity of the polymerase with regard to that particular unconventional nucleotide or combination of unconventional nucleotides used in the assay. Unconventional nucleotides corresponding to all four conventional nucleotides may be included in the reactions, or, alternatively, only one unconventional nucleotide may be included to assess the effect of the mutation(s) on utilization of a given unconventional nucleotide. One approach is to use unconventional nucleotides corresponding to all four nucleotides in a first screen to identify

clones that incorporate more than a reference wild-type clone, and then to monitor the incorporation of individual unconventional nucleotides in a subsequent screen. In the preferred screening mode, only the dideoxynucleotides and dideoxynucleotide analogs of ddATP, ddCTP, and ddTTP would be used since ddGTP is not discriminated against by some DNA polymerases and increases the background signal of any screen

In order to screen for clones with enhanced ability to incorporate dideoxynucleotides, clones identified in first screens utilizing only dideoxynucleotides may then be characterized by their sensitivity to low levels of each of the four dideoxynucleotides in a DNA polymerase nucleotide incorporation assay employing all four dNTPs, a 3 H-TTP tracer, and a low level of each ddNTP. Since incorporation of dideoxynucleotides stops DNA chain elongation, superior ability to incorporate dideoxynucleotides diminishes the incorporation of tritium labeled deoxynucleotides relative to wild-type DNA polymerase. Comparisons of ddNTP concentrations that bring about 50% inhibition of nucleotide incorporation ($I_{50\%}$) can be used to compare ddNTP incorporation efficiency of different polymerases or polymerase mutants. Comparisons of $I_{50\%}$ values for ddATP, ddCTP, ddGTP, and ddTTP can be used to identify mutants with reduced selectivity for particular bases. Such mutants would be expected to produce more uniform DNA sequencing ladders.

In order to measure incorporation of individual ddNTPs, cocktails are prepared which consist of varying concentrations of the ddNTP of interest, and a total of 200 μ M of each nucleotide triphosphate. For example, the incorporation of ddATP by wild type JDF-3 polymerase may be measured at 0, 40, 80, 120 and 160 μ M ddATP. In these reactions, dATP concentrations would be adjusted to 200, 160, 120, 80, and 40 μ M, respectively, so that the total amount of adenine nucleotide triphosphate is 200 μ M. In comparison, mutants may be assayed using ddATP concentrations of 0, 5, 10, and 20 μ M ddATP, and adjusted dATP concentrations of

200, 195, 190, and 180 μ M, respectively (dATP + ddATP = 200 μ M). Additional cocktails are prepared to similarly measure ddCTP, ddGTP, and ddTTP incorporation.

Incorporation of nucleotides under the concentration parameters described above may be measured in extension reactions by adding, for example, 1 μ l of appropriately diluted bacterial extract (i.e., heat-treated and clarified extract of bacterial cells(see Example 1, part M) expressing a cloned polymerase or mutated cloned polymerase) to 10 μ l of each nucleotide cocktail, followed by incubation at 72°C for 30 minutes. Extension reactions are quenched on ice, and then 5 μ l aliquots are spotted immediately onto DE81 ion-exchange filters (2.3cm; Whatman #3658323). Unincorporated label is removed by 6 washes with 2xSCC (0.3M NaCl, 30mM sodium citrate, pH 7.0), followed by a brief wash with 100% ethanol. Incorporated radioactivity is then measured by scintillation counting. Reactions that lack enzyme are also set up along with sample incubations to determine “total cpms” (omit filter wash steps) and “minimum cpms”(wash filters as above).

Cpms bound is proportional to the amount of polymerase activity present per volume of bacterial extract. The volume of bacterial extract (generally about 0.25-1 μ l) which brings about incorporation of approximately 10,000 cpms is determined for use in subsequent nucleotide analog incorporation testing.

Genes for mutant DNA polymerases generated by random mutagenesis may be sequenced to identify the sites and number of mutations. For those mutants comprising more than one mutation, the effect of a given mutation may be evaluated by introduction of the identified mutation to the *exo⁻* progenitor gene by site-directed mutagenesis in isolation from the other mutations borne by the particular mutant. Screening assays of the single mutant thus produced will then allow the determination of the effect of that mutation alone.

F. Expression of Mutated Family B DNA Polymerase According to the Invention

Methods known in the art may be applied to express and isolate the mutated forms of Family B DNA polymerase according to the invention. Many bacterial expression vectors contain sequence elements or combinations of sequence elements allowing high level inducible expression of the protein encoded by a foreign sequence. For example, as mentioned above, bacteria expressing an integrated inducible form of the T7 RNA polymerase gene may be transformed with an expression vector bearing a mutated DNA polymerase gene linked to the T7 promoter. Induction of the T7 RNA polymerase by addition of an appropriate inducer, for example, isopropyl- β -D-thiogalactopyranoside (IPTG) for a lac-inducible promoter, induces the high level expression of the mutated gene from the T7 promoter (see Gardner & Jack, 1999, supra).

Appropriate host strains of bacteria may be selected from those available in the art by one of skill in the art. As a non-limiting example, *E. coli* strain BL-21 is commonly used for expression of exogenous proteins since it is protease deficient relative to other strains of *E. coli*. BL-21 strains bearing an inducible T7 RNA polymerase gene include WJ56 and ER2566 (Gardner & Jack, 1999, supra). For situations in which codon usage for the particular polymerase gene differs from that normally seen in *E. coli* genes, there are strains of BL-21 that are modified to carry tRNA genes encoding tRNAs with rarer anticodons (for example, argU, ileY, leuW, and proL tRNA genes), allowing high efficiency expression of cloned protein genes, for example, cloned archaeal enzyme genes (several BL21-CODON PLUSTM cell strains carrying rare-codon tRNAs are available from Stratagene, for example).

There are many methods known to those of skill in the art that are suitable for the purification of a modified DNA polymerase of the invention. For example, the method of Lawyer et al. (1993, PCR Meth. & App. 2: 275) is well suited for the isolation of thermostable DNA polymerases expressed in *E. coli*, as it was designed originally for the isolation of Taq

polymerase. Alternatively, the method of Kong et al. (1993, J. Biol. Chem. 268: 1965, incorporated herein by reference) may be used, which employs a heat denaturation step to destroy host proteins, and two column purification steps (over DEAE-Sepharose and heparin-Sepharose columns) to isolate highly active and approximately 80% pure thermostable DNA polymerase. Further, as detailed in Example 1, part N, below, DNA polymerase mutants may be isolated by an ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose columns, or by adsorption of contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column.

G. Preparation of *Thermococcus* species JDF-3 Thermostable DNA Polymerase With Reduced Discrimination

To prepare thermostable Family B polymerases which exhibit reduced discrimination for dideoxynucleotide triphosphates (ddNTPs), the DNA sequence encoding a 3' to 5' exonuclease- deficient (D141A) Family B polymerase from the hyperthermophilic archaeon *Thermococcus* species JDF-3 was subjected to random mutagenesis using "error-prone PCR" as described herein, and cloned into the bacteriophage lambda Zap®II. The polymerase from JDF-3 was chosen due to superior processivity, polymerization rate and ddNTP incorporation relative to the Family B DNA polymerase from *Pyrococcus furiosus* (Pfu) (see Table IV, below). The library of mutants was plated on *E. coli* hosts and the proteins present in the lytic plaques were transferred to a solid support that was then immersed in a buffer containing DNA template and all four α -³³P labeled dideoxynucleotides. Mutants that incorporated the labeled dideoxynucleotide produced signals that corresponded to their ability to incorporate the α -³³P ddNTPs. Isolated clones were then characterized by their sensitivity to low levels of each of the four dideoxynucleotides in a DNA polymerase nucleotide incorporation assay employing all four dNTPs and a ³H-TTP tracer. Since incorporation of dideoxynucleotides stops DNA chain

elongation, superior ability to incorporate dideoxynucleotides diminishes the incorporation of tritium labeled deoxynucleotides. The unmutated progenitor DNA polymerase rarely incorporates dideoxynucleotides and is only 50% inhibited at high ddNTP levels (100-160 micromolar each ddNTP). The mutant enzymes show 50% inhibition at 5 to 40 micromolar concentrations of ddNTP and improved incorporation was observed for all four ddNTPs (ddATP, ddCTP, ddTTP and ddGTP; see Tables V and VI in Example 1, below).

The incorporation of non-conventional nucleotides was also evaluated through use of purified mutant polymerases in cycle sequencing, with α -³³P labeled ddNTPs present at 0.021 μ M and dNTPs present at 2.1 μ M each. The mutants readily utilized all four dideoxynucleotides and produced sequencing ladders that compared favorably to Thermo Sequenase®, which uses an F667Y Taq DNA polymerase mutant (VanderHorn et al., 1997, BioTechniques 22: 758).

The domains of relevance in 17 of the 40 purified mutants were sequenced. Most randomly mutated clones contained more than one mutation in the regions sequenced but all mutants contained mutations at one of three sites. Mutations predicted to confer an enhanced ddNTP uptake phenotype were introduced into the progenitor exonuclease deficient DNA polymerase sequence by site-directed mutagenesis to eliminate ancillary mutations which were not expected to contribute to the improved dideoxynucleotide uptake phenotype.

Sixteen of the seventeen JDF-3 DNA polymerase mutations were found in region II (motif A) on either side of the tyrosine in the consensus sequence 404 DxxSLYPSII 413. These mutations consisted of DFRSLYLSII (P410L), DFRSHYPSII (L408H) and DFRSFYPSII (L408F). Therefore, the LYP motif of region II appears to be important in ddNTP discrimination in the JDF-3 Family B polymerase.

The prior art modification of the tyrosine corresponding to Y409 in JDF3 Family B DNA polymerase is recognized for its positioning in the nucleotide binding pocket. As shown herein, however, modification of the residues neighboring Y409 (L408H or L408F or P410L) had the unexpected effect of profoundly altering nucleotide binding, particularly with respect to ddNTP incorporation.

The only JDF-3 DNA polymerase mutation leading to enhanced incorporation of non-conventional nucleotides occurring outside of region II is an alanine (ala or A) to threonine (thr or T) conversion at position 485 in region III (A485T). This site is two residues upstream of KX₃NSXYG (Jung et al., 1990, supra; Blasco et al., 1992, supra; Dong et al., 1993, J. Biol. Chem. 268:21163; Zhu et al., 1994, Biochem. Biophys. Acta 1219:260; Dong and Wang, 1995, J. Biol. Chem. 270:21563) (referred to as region III or motif B) which is functionally, but not structurally (Wang et al., 1997, supra), analogous to KX₃(F/Y)GX₂YG in helix O of the Family A DNA polymerases. In Family A DNA polymerases, such as the Klenow fragment and Taq DNA polymerases, the O helix contains amino acids that play a major role in dNTP binding (Astatke et al., 1998, J. Mol. Biol. 278:147; Astatke et al., 1995, J. Biol. Chem. 270:1945; Polesky et al., 1992, J. Biol. Chem 267:8417; Polesky et al., 1990, J. Biol. Chem. 265:14579; Pandey et al., 1994, J. Biol. Chem. 269:13259; Kaushik et al., 1996, Biochem. 35:7256). Specifically, helix O contains the F (F762 in the Klenow fragment; F667 in Taq) which confers ddNTP discrimination in Family A DNA polymerases (KX₃(F/Y)GX₂YG) (Tabor and Richardson, 1995, supra).

The effect of the A485T mutation on ddNTP incorporation in the JDF-3 DNA polymerase is surprising since the RB69 and *Thermococcus gorgonarius* crystal structures (Hopfner et al., 1999, supra) show it facing away from the proposed active site of the nucleotide binding surface. Moreover, the type of side chain conferring ribose selectivity in archaeal

Family B DNA polymerases (A: small, non-polar) is different from that of the bulky, aromatic Y and F residues that dictate ddNTP discrimination in Family A DNA polymerases (Tabor and Richardson, 1995, supra). Additionally, this position (A485) is not well conserved among either DNA polymerase family and is not included in the consensus sequence for this domain (Braithwaite and Ito, 1993, supra), implying a lack of critical importance in dNTP recognition.

A JDF-3 double mutant was constructed that contains mutations P410L and A485T. In dideoxynucleotide cycle sequencing, the banding pattern intensity demonstrated by the double mutant was extremely uniform, suggesting little if any preference for any dNTP over its corresponding ddNTP (See Figure 8 and Example 1Q). This polymerase characteristic improves the accuracy of base calling in automated sequencing. We presume that combinations of P410L and A485 mutations, L408H and A485 mutations, and L408F and A485 mutations would result in enzymes that exhibit improved ddNTP incorporation. The efficiency of dideoxynucleotide incorporation by such double mutant enzymes may also be characterized or quantitated by measurement of the $I_{50\%}$ as described herein to determine the relative degree of improvement in incorporation.

EXAMPLES

The following examples are offered by way of illustration only and are by no means intended to limit the scope of the claimed invention.

EXAMPLE 1.

A. Cloning a DNA polymerase gene from *Thermococcus species* JDF-3 DNA polymerase.

A *Thermococcus* species was cultured from submarine samples taken from the Juan de Fuca ridge. Genomic DNA was isolated and used to prepare a genomic DNA library in ZAP II (Stratagene) using standard procedures. The lambda library was plated on XL1-Blue MRF' *E. coli* and screened for clones with DNA polymerase activity using a variation of the method

described by Sagner *et al.* (Sagner, G., Ruger, R., and Kessler, C. (1991) *Gene* 97:119-123). Plaques containing active polymerase were cored and stored in SM buffer. Positive primary plaques were re-plated and re-assayed to allow purification of isolated clones. Secondary clones were excised according to the instructions provided with the ZAP II system (Stratagene), and the DNA sequence of the insert determined (Figure 1).

The translated amino acid sequence of the JDF-3 DNA polymerase is shown in Figure 2. Amino acid sequence alignments show that JDF-3 DNA polymerase exhibits homology to the class of DNA polymerases referred to as Family B.

Recombinant JDF-3 DNA polymerase was purified as described below (see “Purification of JDF-3” (method 1)). The biochemical properties of JDF-3 DNA polymerase have been compared to those of other commercially available archaeal DNA polymerases. The results shown in Table IV and V indicated that, compared to other enzymes, JDF-3 exhibits higher processivity, a faster polymerization rate (K_{cat}), and a greater tendency to utilize ddNTPs. JDF-3 DNA polymerase was therefore chosen for development of a DNA sequencing enzyme.

Table IV. Polymerase Activities of Archaeal Family B DNA Polymerases

Polymerase	Specific Activity (U/mg) x 10 ⁴				
	Activated DNA	Primed M13	DNA (nM)	dNTP (μM each)	
Pfu	2.6 ± .07	4.1 ± .07	2.0 ± .02	0.7	16 ± 2
exo ⁻ Pfu		2.3	0.5		12
JDF-3	1.2 ± .07	5.2	2.0		16 ± 2
Vent	1.8 ^a	0.7 ^a	0.1 ^a		57 ^a

^aH. Kong, R.B. Kucera, and W.E Jack, *J. Biol. Chem.* 268, 1965 (1993).

B. Intein removal from the gene encoding JDF-3 DNA polymerase.

By alignment to Family B DNA polymerase sequences, the JDF-3 DNA polymerase clone was found to contain an intein sequence (Figures 3 and 4). To improve expression of

recombinant JDF-3 polymerase, the intein was removed by inverse PCR. PCR primers were designed to prime immediately upstream and downstream to the sequence coding for the intein termini, and were oriented such that the 3' ends of the primers were pointed away from the intein. The primers were also modified with 5'-phosphate groups to facilitate ligation. The plasmid/insert sequence was PCR amplified and circularized by standard methods.

C. Construction of a JDF-3 DNA polymerase mutant with diminished 3'-5' exonuclease activity.

DNA polymerases lacking 3'-5' exonuclease (proofreading) activity are preferred for applications requiring nucleotide analog incorporation (e.g., DNA sequencing) to prevent removal of nucleotide analogs after incorporation. The 3'-5' exonuclease activity associated with proofreading DNA polymerases can be reduced or abolished by mutagenesis. Sequence comparisons have identified three conserved motifs (exo I, II, III) in the 3'-5' exonuclease domain of DNA polymerases (reviewed V. Derbyshire, J.K. Pinsonneault, and C.M. Joyce, Methods Enzymol. **262**, 363 (1995)). Replacement of any of the conserved aspartic or glutamic acid residues with alanine has been shown to abolish the exonuclease activity of numerous DNA polymerases, including archaeal DNA polymerases such as Vent (H. Kong, R.B. Kucera, and W.E. Jack, J. Biol. Chem. **268**, 1965 (1993)) and *Pfu* (Stratagene, unpublished). Conservative substitutions lead to reduced exonuclease activity, as shown for mutants of the archaeal 9° N-7 DNA polymerase (M.W. Southworth, H. Kong, R.B. Kucera, J. Ware, H. Jannasch, and F.B. Perler, Proc. Natl. Acad. Sci. **93**, 5281 (1996)).

JDF-3 DNA polymerase mutants exhibiting substantially reduced 3'-5' exonuclease activity were prepared by introducing amino acid substitutions at the conserved 141D or 143E residues in the exo I domain. Using the CHAMELEON® Double-Stranded, Site-Directed

Mutagenesis Kit (Stratagene), the following JDF-3 mutants were constructed: D141A, D141N, D141S, D141T, D141E and E143A.

To analyze JDF-3 mutant proteins, the DNA sequence encoding JDF-3 DNA polymerase was PCR amplified using primers GGG AAA **CAT** ATG ATC CTT GAC GTT GAT TAC (where NdeI site in bold and start codon underlined) and GGG AAA **GGA TCC** TCA CTT CTT CTT CCC CTT C (where BamHI site shown in bold type). The PCR products were digested, purified, and ligated into a high expression level vector using standard methods. Plasmid clones were transformed into BL21(DE3). Recombinant bacterial clones were grown using standard procedures and JDF-3 polymerase mutants were expressed in the absence of induction. The exonuclease and polymerase activities of recombinant clones were assayed using bacterial lysates. Typically, crude extracts were heated at 70°C for 15-30 minutes and then centrifuged to obtain a cleared lysate.

There are several methods of measuring 3' to 5' exonuclease activity known in the art, including that of Kong et al. (Kong et al., 1993, J. Biol. Chem. 268: 1965) and that of Southworth et al. (Southworth et al., 1996, Proc. Natl. Acad. Sci. U.S.A. 93: 5281), the full contents of both of which are hereby incorporated by reference. The exonuclease activity of wild type and active mutant polymerases as measured by the Kong et al. method were as follows:

Exo activity (U/mg):

Wt 915

D141A7

D141N953

D141S 954

D141T 0.5

D141E 940

E143A 0.3

The combination exonuclease mutant D141A+E143A was made as described in section L.

The E143A JDF-3 mutant (clone #550) exhibited significantly reduced 3'-5' exo activity and was chosen for further mutagenesis to improve incorporation of ddNTP and other nucleotide analogs. Other JDF-3 mutants with substantially reduced exonuclease activity could have been used for this purpose, such as the JDF-3 D141T mutant. For experiment or applications requiring the absolute elimination of 3' to 5' exonuclease activity, the double mutant D141A + E143A was preferred.

D. Error-prone PCR amplification of the JDF-3 DNA polymerase gene.

Random mutations were introduced into exo⁻ JDF-3 by amplifying the entire gene (clone #550) under conditions which did not support high fidelity replication. To broaden the spectrum of potential mutations, three different PCR enzymes were used under error-prone conditions.

In the preferred mode, ten reactions of 100µl each were amplified with each PCR enzyme.

i. Amplification with *Taq* DNA polymerase:

Reaction Mixture

1x	magnesium free <i>Taq</i> Buffer (Stratagene catalog #200530)
1mM	each TTP and dCTP
0.2 mM	each dGTP and dATP
2ng/µl	Primer 923 (also called 490)
2ng/µl	Primer 721
0.05u/µl	Taq2000 (Stratagene catalog #600195)

1.5mMMgCl₂

0.5mM MnCl₂

0.1pM plasmid DNA (clone #550)

Cycling Parameters

PCRs were carried out using Stratagene's ROBOCYCLER™40 Temperature Cycler with a Hot Top assembly. The following cycling conditions were used:

- 1) 95°C for 1 minute
- 2) 95°C for 1 minute
- 3) 54°C for 1 minute
- 4) 72°C for 2.5 minutes
- 5) Repeat steps 2 to 4 thirty times.

ii. Amplification with *exo⁻* JDF-3 DNA polymerase

Reaction Mixture

1x magnesium free *Taq* Buffer (Stratagene catalog #200530)

450μM each deoxynucleotide (dGTP, dATP, TTP and dCTP)

2ng/μl Primer 923 (also called 490)

2ng/μl Primer 721

0.1u/μl *exo⁻* JDF-3 DNA polymerase

0.5mMMnCl₂

0.1pM plasmid DNA (clone #550)

Cycling Parameters

PCRs were carried out using Stratagene's ROBOCYCLER™40 Temperature Cycler with a Hot Top assembly. The following cycling conditions were used:

- 1) 95°C for 1 minute
- 2) 95°C for 1 minute
- 3) 54°C for 1 minute
- 4) 72°C for 2.5 minutes
- 5) Repeat steps 2 through 4 thirty times.

iii. Amplification with *exo⁻* *Pfu* DNA polymerase

Reaction Mixture

- 1x TAQPLUS® Precision Buffer (Stratagene catalog #600210)
- 200µM each deoxynucleotide (dGTP, dATP, TTP, dCTP)
- 2ng/µl Primer 923 (also called 490)
- 2ng/µl Primer 721
- 0.05u/µl *exo⁻* *Pfu* DNA polymerase (Stratagene catalog number 600163)
- 0.1pM plasmid DNA (clone #550)

Cycling Parameters

PCRs were carried out using Perkin-Elmer's 9600 Temperature Cycler. The following cycling conditions were used:

- 1) 95°C for 1 minute
- 2) 95°C for 1 minute
- 3) 53°C for 1 minute
- 4) 72°C for 5 minutes
- 5) Repeat steps 2 through 4 thirty times.

Forward Primers

Earlier versions of the mutant libraries were made with the forward primer 461, which contains an *EcoR* I site. When products amplified with primers 461 and 923 were restriction digested and cloned into the lambda vector as described in the following section, JDF-3 DNA polymerase was synthesized as a fusion protein with the first 39 amino acids of the vector-encoded β -galactosidase (*lacZ*) protein.

Primer 461 5' TCAGATGAATTCGATGATCCTTGACGTTGATTAC 3'

EcoR I JDF-3 specific sequence

The clones isolated using primer 461 were designed as p#.

The preferred mode of amplification and cloning utilizes the forward primer 721, which also contains an *EcoR* I site followed by three consecutive in-frame stop codons and a ribosome binding site. This arrangement allows the JDF-3 DNA polymerase to be translated without any vector-derived residues at the amino terminus. The clones isolated from libraries constructed with the forward primer 721 were designated as 1-# to differentiate them from the p# series of clones.

Primer 721

5' GAGAGAATTCATAATGATAAGGAGGAAAAAATTATGATCCTTGACGTTGATTAC3'

EcoR I 3x STOP JDF-3 specific sequence

Reverse Primers

Primer 923 (490) 5' TCAGATCTCGAGTCACTTCTTCTTCCCCTTC 3'

Xho I JDF-3 specific sequence

E. Preparing PCR products for cloning.

PCR products were purified and concentrated with the STRATAPREP™ PCR Purification kit (Stratagene catalog number 400771). The PCR products were then digested with 50 units of *Xho* I and 50 units of *EcoR* I in 1.5x Universal buffer (10x Universal Buffer: 1M

KOAc, 250mM Tris-Acetate (pH 7.6), 100mM MgOAc, 5mM β -mercaptoethanol and 100 μ g/ml BSA) for one hour at 37°C. The digested samples were run on a 1% agarose, 1x TBE gel and visualized with ethidium bromide staining. The 2.3kb amplification product was gel isolated and purified with the STRATAPREP™ DNA Gel Extraction Kit (Stratagene catalog number 400766).

F. Cloning PCR Inserts into the Uni-Zap®XR Lambda Vector.

200ng of purified amplification product was ligated with 1 μ g of UNI-ZAP®XR Lambda Vector (Stratagene catalog #239213), which had been predigested with *Eco*R I and *Xho* I and then dephosphorylated with alkaline phosphatase (Stratagene catalog number 237211). The DNAs were ligated using 2 units of T4 DNA ligase (Stratagene catalog number 600011) and 0.5mM ATP in 1x ligase buffer (50mM Tris-HCL (pH 7.5), 7mM MgCl₂, 1mM DTT) in reaction volumes of 10 to 15 μ l. Ligations were carried out at 16°C for a minimum of 16 hours.

G. Lambda Packaging and Bacterial Infection.

Two microliters of each ligation reaction were packaged with GIGAPACK® III Gold Packaging extract (Stratagene catalog #200201) for 90 minutes at room temperature before being stopped with 500 μ l SM buffer (50mM Tris pH 7.5, 100mM NaCl, 8mM MgSO₄ and 0.01% gelatin) and 20 μ l of chloroform. The packaged lambda vectors were plated on *E. coli* XL1-Blue MRF' host cells.

H. Dideoxynucleotide Screening.

Mutant polymerase libraries were screened using a variation of the technique used by Sagner *et al* (Sagner, G., Ruger, R., and Kessler, C. (1991) *Gene* 97:119-123). Lambda phage clones were plated at a density of 10-20 plaques per square centimeter. Proteins present in the plaques were transferred to filters and moistened with polymerase screening buffer (50mM Tris (pH 8.0), 7mM MgCl₂, 3mM β -ME). The filters were kept between layers of plastic wrap and glass while the host cell proteins were heat-inactivated by incubation at 65°C for 30 minutes. The

heat-treated filters were transferred to fresh plastic wrap and approximately 35µl of the polymerase assay cocktail was added for every square centimeter of filter. Polymerase assay cocktail consisted of 1x cloned Pfu magnesium-free buffer (Stratagene catalog #200534), 125ng/ml activated calf thymus or salmon sperm DNA, 1.29 µCi/ml α -³³P ddNTP (Amersham), and 0.5mM MnCl₂. Initial screening was done in the presence of MnCl₂, but the preferred method was to screen in 1X Taq Polymerase buffer (1.5 mM MgCl₂). The filters were sandwiched between plastic wrap and glass again and incubated at 65°C for one hour, and then at 70°C for one hour and 15 minutes. The filters were washed three times in 2x SSC for five minutes each time before being rinsed twice in 100% ethanol and dried on a vacuum dryer. The filters were exposed to X-ray film for approximately 16 hours. Plaques corresponding to strong signals were cored and placed in SM buffer. The positive primary plaques were replated at more dilute concentrations and assayed under essentially similar conditions to allow the purification of isolated plaques.

Dye-dideoxynucleotide Screening

To detect mutant polymerases with improved capacity for dye-deoxynucleotide and dye-dideoxynucleotide utilization, the JDF-3 mutant DNA polymerase library was screened as described previously with the following exceptions:

Polymerase assay cocktail for Flu-12-dUTP screening:

0.9X Taq Buffer (Stratagene Catalog #200435), 65 µM dATP, 65 µM dCTP, 65 µM dGTP, 65 µM dTTP, 0.3 µM Fluorescein-12-dUTP (Stratagene in-house production), 0.75 µg/µl activated calf thymus DNA.

Polymerase assay cocktail for ROX ddNTP

1X Taq Buffer, 0.9 µM dATP, 0.9 µM dCTP, 0.9 µM dGTP, 0.9µl TTP, 0.6 µM ROX ddATP (New England Nuclear (NEN) NEN478), 0.06 µM ROX ddGTP (NEN NEL479), 0.06

μ M ROX ddCTP (NEN NEL477), 0.06 μ M ROX ddUTP (NEN NEL476), 0.84 μ g/ μ l activated calf thymus DNA. (Note: A screening system without ROX ddGTP is the preferred method since DNA polymerases do not discriminate against ddGTP).

Polymerase assay cocktail for Fluoresceine ddUTP

1X Taq Buffer, 70 μ M dATP, 70 μ M dTTP, 70 μ M dCTP, 15 μ M dTTP, 1 μ M Fluoresceine-12-ddUTP (NEN NEL401), 0.84 μ g/ μ l activated calf thymus DNA.

Antibody binding to fluoresceine

The filters were blocked overnight with 1% non-fat dry milk dissolved in TBST (50 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20) at 4°C. The filters were washed briefly in TBST before alkaline phosphatase conjugated anti-fluoresceine antibody from the Illuminator kit (Stratagene catalog #300360) was added at a 1/10,000 dilution in 50 ml TBST. The antibody was detected with NBT/BCIP at concentrations of 0.3 mg/ml and 0.15 mg/ml respectively in a buffer composed of 100 mM Tris pH 9.5, 100 mM NaCl, and 5 mM MgCl₂.

Antibody binding to Rhodamine

Anti-ROX antibody (Zymed cat. no. 71-3600 rabbit Rhodamine (5-ROX polyclonal, 1 mg/ml)) was diluted to 1:1000 in TBST. The blocked filters were blotted briefly to remove excess moisture then laid on plastic wrap and covered with 2.5 ml of the diluted antibody solution. An additional sheet of plastic wrap was laid over the filters before incubation at room temperature for 1 hour. The filters were washed briefly three times with TBST, then washed three times with gentle agitation for 15 minutes each time. The washed filters were incubated with alkaline phosphatase conjugated goat anti-rabbit antibodies diluted 1:5000 in TBST. The filters were incubated with the antibody for one hour then detected with NBT/BCIP as described previously.

I. Dideoxynucleotide Qualification

Lambda phage clones which incorporated ^{33}P -labeled ddNTPs in the primary library screen were re-screened to verify polymerase activity and to assess the contribution of the divalent metal ion to ^{33}P -ddNTP incorporation. The clones selected during this round of screening were designated as p#. These clones all contained an amino-terminal tag, as discussed in the section entitled "Forward Primers". Figure 5 shows that clones p1, p2, p3, p6, p7, p8, p9, p10, p11, p12, p14, p15, and p16 exhibited wild type levels of DNA polymerase activity, based upon similarity in signal strength to the parental #550 clone (Figure 5, panel 3). Although initial screening was carried out in the presence of 0.5mM MnCl_2 , all of the clones except p9 and p10 were able to incorporate ^{33}P -labeled ddNTPs to at least some extent in the presence of 1.5mM MgCl_2 (panel 2), with clones p2, p4, p8, p11, p12, p13, p14, p15, p17, and p18 producing the highest signals.

Eighteen mutants were chosen for evaluation. One microliter of phage isolated from each purified plaque was placed on each of three *E. coli* XL1-Blue MRF' lawns. Phage containing a parental copy of *exo⁻* JDF3 DNA (#550 clone) were also spotted on the grid. The plaques formed by the phage were transferred to filters and treated as described in the preceding screening section with the exception of the final buffer composition. The buffers used for each filter (filters 1-3) are as follows:

Filter 1: Dideoxynucleotide screen with manganese chloride

1x	Taq DNA polymerase magnesium-free buffer
1.28	$\mu\text{Ci/ml}$ ^{33}P ddNTPs
0.5	$\mu\text{g}/\mu\text{l}$ Activated Calf Thymus DNA (Sigma)
0.5	mM MnCl_2

Filter 2: Dideoxynucleotide screen with magnesium chloride

1x	Taq DNA polymerase buffer (containing 1.5mM MgCl_2 , catalog #200435)
----	--

1.28 $\mu\text{Ci/ml}$ ^{33}P ddNTP

0.5 $\mu\text{g}/\mu\text{l}$ Activated Calf Thymus DNA (Sigma)

Filter 3: Deoxynucleotide screen with magnesium chloride

1x Taq DNA polymerase buffer

0.072 mM dGTP, dCTP and TTP

40 μM dATP

0.5 $\mu\text{g}/\text{ml}$ Activated Calf Thymus DNA (Sigma)

0.01 μCi α - ^{33}P dATP.

Results are shown in Figure 5.

Dye-dideoxynucleotide Qualification

As described in the previous segments, primary lambda clones were spotted on an *E. coli* lawn and re-screened with the appropriate antibody or antibodies.

J. Excision of Lambda Clones.

When incubated with helper phage under suitable conditions, Lambda Zap™ vectors are designed to produce phagemid copies of the part of the vector containing pBluescript (SK-) and the insert. This process yields a plasmid (pBluescript SK-) vector carrying the same insert that was contained in the lambda clone. Excision of clones with the desired phenotype was carried out according to the instructions in the EXASSIST™ system (Stratagene catalog #200253).

K. Sequence Analysis of Mutants.

The mutants were sequenced by Sequetech Corporation(Mountain View, California) using the following primers:

Primer 3 (or primer G) 5' CCAGCTTTCCAGACTAGTCGGCCAAGGCC 3'

Primer 5 (or JDF3-1128) 5' AACTCTCGACCCGCTG 3'

L. Dideoxynucleotide mutagenesis.

To conclusively identify the amino acids contributing to reduced ddNTP discrimination, individual point mutations were introduced into the *exo*⁻ JDF-3 #550 clone using the QUIKCHANGE™ Site-Directed Mutagenesis Kit (Stratagene catalog #200518). The following mutants were prepared: L408H, L408F, P410L, A485T, S345P, D373Y, A619V, and L631V. In addition, a double mutant (P410L/A485T) was constructed by introducing the A485T mutation into the *exo*⁻ JDF-3 P410L mutant clone. To completely eliminate all 3' to 5' exonuclease activity, the mutation D141A was added to all clones. A pre-existing 5' to 3' exonuclease mutation (E143A) was present in the parental template JDF-3 550.

Dye-dideoxynucleotide mutagenesis

To conclusively identify amino acids responsible for contributing to reduced discrimination of dye nucleotides, the mutation S345P was generated alone and in combination with the P410L and P410L + A485T.

M. Preparation of heat-treated bacterial extracts.

E. coli SOLR cells containing the excised plasmid were grown overnight at 37°C. The cells contained in 500µl of culture were collected by microcentrifugation. The cell pellets were resuspended in 50µl of 50mM Tris (pH 8.0). Lysozyme was added to a final concentration of 1µg/µl, and the cells were lysed during a 10 minute incubation at 37°C, followed by 10 minutes at 65°C. The heat-inactivated cell material was collected by microcentrifugation and the supernatants were assayed for dNTP and ddNTP incorporation as described below.

N. Purification of JDF-3 and JDF-3 polymerase mutants.

One method for purifying *exo*⁻ JDF-3 DNA polymerase involves ammonium sulfate fractionation, followed by Q Sepharose and DNA cellulose columns. A second method has been developed to allow rapid purification of JDF-3 polymerase mutants, and entails adsorption of

contaminants on a HiTrap Q column, followed by gradient elution from a HiTrap heparin column (section iii).

i. Preparation of bacterial lysate.

Frozen cell paste (3-14 grams) was resuspended with 3x volume of lysis buffer, consisting of 50mM Tris-HCl (pH 8.0), 1 mM EDTA, and 10 mM β -mercaptoethanol. Lysozyme was added to 0.2mg/ml and PMSF was added to 1mM final concentration. The cells were lysed on ice over a period of 1 hour. The lysate was then sonicated for 2 minutes (90% duty, level of 2x2.5, 1x3.0). Following sonication, the lysate was heated at 65°C for 15 minutes to denature bacterial proteins. The heated lysate was then centrifuged for 30 minutes at 14.5K rpm in a Sorvall RC-2B centrifuge using a Sorvall SS-34 rotor, and the supernatant was recovered.

ii. Ammonium sulfate fractionation and Q Sepharose/DNA cellulose chromatography (method 1)

Ammonium sulfate was added to the bacterial lysate to a final concentration of 45%. The ammonium sulfate was added over a period of 15 minutes, and the mixture was stirred for an additional 30 minutes. The mixture was centrifuged as described above, and the supernatant was recovered. Additional ammonium sulfate was then added to bring the final concentration to 65%. The mixture was centrifuged as described above, and the supernatant removed. The pellet was resuspended in 10ml of buffer A consisting of 50mM Tris-HCl (pH 7.5), 1 mM EDTA, 10mM β -mercaptoethanol, 0.1% (v/v) Tween 20, and 10% (v/v) glycerol. The supernatant was dialyzed overnight against 2 changes of buffer A (3 liters each).

The dialysate was loaded onto a 2.6 x 9.4cm Q-Sepharose Fast Flow column (50mls), pre-equilibrated in buffer A. The column was washed with buffer A until the absorbance (OD_{280})

approached baseline. The column was then eluted with a gradient from 0 to 1M NaCl/buffer A. Fractions were collected, and analyzed by SDS-PAGE and DNA polymerase activity assays (see below). Active protein typically eluted between 130 and 240mM NaCl. Active fractions were pooled and dialyzed overnight against 2 changes of buffer B (3 liters each), consisting of 50mM Tris-HCl (pH 7.5), 1 mM EDTA, 10mM β -mercaptoethanol, 0.1% (v/v) Tween 20, 10%(v/v)glycerol, and 50mM NaCl.

The Q-Sepharose eluate was then loaded onto a 1.6 x 4.9cm (10mls) DNA cellulose column, equilibrated in buffer B. The column was washed with buffer B until the absorbence (OD₂₈₀) approached baseline. The column was then eluted with a gradient from 50 to 1000mM NaCl/buffer A. Fractions were collected, and analyzed by SDS-PAGE and DNA polymerase activity assays. Active protein typically eluted between 280 and 360mM NaCl. Active fractions were pooled and dialyzed overnight against JDF-3 final dialysis buffer, consisting of 25mM Tris-HCl (pH 7.5), 100mM KCl, 0.1mM EDTA, 1mM DTT, 0.1% (v/v) Tween 20, 0.1% (v/v) Igepal 630, 10 μ g/ml BSA, and 50% (v/v) glycerol.

iii. HiTrap Q/HiTrap heparin chromatography (method 2)

The preferable method for rapid purification of multiple mutants is as follows. Bacterial cell lysates were prepared as described for method 1, except that Tween 20 and Igepal CA 630 were added to a final concentration of 0.01% (v/v) just prior to the heat denaturation step, and a heat denaturation temperature of 72°C was used.

The lysate was loaded onto a 1.6 x 2.5cm (5mls) HiTrap Q column (pre-packed column from Pharmacia), pre-equilibrated in buffer C consisting of 50mM Tris-HCl (pH 8.2), 1mM EDTA, 10mM β -mercaptoethanol, 0.1% (v/v) Tween 20, and 0.1% (v/v) Igepal CA 630. The column was washed with buffer C until the absorbence (OD₂₈₀) approached baseline. The flow

through fractions (OD₂₈₀ absorbance above background) were collected and then loaded onto a 1.6 x 2.5cm (5mls) HiTrap heparin column (pre-packed column from Pharmacia), pre-equilibrated in buffer D consisting of 50mM Tris-HCl (pH 8.2), 1mM EDTA, 1mM DTT, 0.1% (v/v) Tween 20, 0.1% (v/v) Igepal CA 630, and 10% glycerol (v/v). The column was washed with buffer D until the absorbance (OD₂₈₀) approached baseline. The column was then eluted with a gradient from 0 to 1M KCl/buffer D. Fractions were collected, and analyzed by SDS-PAGE and DNA polymerase activity assays. Active protein typically eluted between 390 and 560mM NaCl. Active fractions were pooled and dialyzed overnight against JDF-3 final dialysis buffer (see above). Purified polymerases were stored at -20 C.

iv. Analysis of Purified Proteins

The concentrations of JDF-3 and mutant DNA polymerases were determined relative to a BSA standard (Pierce), using Pierce's Coumassie Blue Protein assay reagent. In addition, the purity and relative protein concentrations of different polymerase preparations were verified by SDS-PAGE. Polymerase samples were electrophoresed on 4-20% Tris-glycine gels (Novex), and the gels were silver-stained using standard procedures.

O. Nucleotide Incorporation Assay.

DNA polymerase activity was measured using purified JDF-3 polymerase mutants or heat-treated bacterial extracts prepared from various mutant clones. DNA polymerase activity was measured by monitoring the incorporation of ³H-TTP into activated calf thymus DNA. A typical DNA polymerase reaction cocktail contained:

10mM Tris-HCl, pH 8.8

1.5mM MgCl₂

50mM KCl

0.001% gelatin

200 μ M each dATP, dCTP, dGTP

195 μ M TTP

5 μ M [3 H]TTP (NEN #NET-221H, 20.5Ci/mmol; partially evaporated to remove EtOH)

250 μ g/ml of activated calf thymus DNA (e.g., Pharmacia #27-4575-01)

Incorporation was measured by adding 1 μ l of polymerase samples to 10 μ l aliquots of polymerase cocktail. DNA polymerase samples were diluted in a suitable storage buffer (e.g., 25mM Tris-HCl (pH 7.5), 100mM KCl, 0.1mM EDTA, 1mM DTT, 0.1% (v/v) Tween 20, 0.1% (v/v) Igepal 630, 10 μ g/ml BSA, and 50% (v/v) glycerol). Polymerization reactions were conducted for 30 minutes at 72°C. Extension reactions were quenched on ice, and then 5 μ l aliquots were spotted immediately onto DE81 ion-exchange filters (2.3cm; Whatman #3658323). Unincorporated [3 H]TTP was removed by 6 washes with 2xSSC (0.3M NaCl, 30mM sodium citrate, pH 7.0), followed by a brief wash with 100% ethanol. Incorporated radioactivity was measured by scintillation counting. Reactions that lacked enzyme were also set up along with sample incubations to determine “total cpms” (omit filter wash steps) and “minimum cpms”(wash filters as above).

Cpms bound is proportional to amount of polymerase activity present per volume of bacterial extract. The volume of bacterial extract (0.25-1 μ l) which brought about incorporation of approximately 10,000 cpms was determined for use in subsequent nucleotide analog incorporation testing.

P. Quantitating ddNTP incorporation efficiency.

JDF-3 polymerase mutants were evaluated to assess relative ddNTP incorporation efficiency. Nucleotide incorporation was measured in the presence of varying concentrations of each ddNTP terminator (ddATP, ddCTP, ddGTP, and ddTTP). Since ddNTP incorporation

produces non-extendable termini, polymerization is strongly inhibited for polymerases that incorporate ddNTPs efficiently. Comparisons of ddNTP concentrations that bring about 50% inhibition of nucleotide incorporation ($I_{50\%}$) can be used to compare ddNTP incorporation efficiency of different polymerases or polymerase mutants. Comparisons of $I_{50\%}$ values for ddATP, ddCTP, ddGTP, and ddTTP can be used to identify mutants with reduced selectivity for particular bases. Such mutants would be expected to produce more uniform DNA sequencing ladders.

To measure incorporation of individual ddNTPs, cocktails were prepared which consisted of varying concentrations of the ddNTP of interest, and a total of 200 μ M of each nucleotide triphosphate. For example, the incorporation of ddATP by wild type JDF-3 polymerase was measured at 0, 40, 80, 120 and 160 μ M ddATP. In these reactions, dATP concentrations were adjusted to 200, 160, 120, 80, and 40 μ M, respectively, so that the total amount of adenine nucleotide triphosphate was 200 μ M. In comparison, mutants were assayed using ddATP concentrations of 0, 5, 10, and 20 μ M ddATP, and adjusted dATP concentrations of 200, 195, 190, and 180 μ M, respectively (dATP + ddATP = 200 μ M). Additional cocktails were prepared to measure ddCTP, ddGTP, and ddTTP incorporation. To assess ddNTP incorporation by JDF-3 mutants at 3 different ddNTP concentrations, 12 reaction cocktails were prepared consisting of:

10mM Tris-HCl, pH 8.8

1.5mM MgCl₂

50mM KCl

0.001% gelatin

5 μ M [³H]TTP (NEN #NET-221H, 20.5Ci/mmol; partially evaporated to remove EtOH)

250 μ g/ml of activated calf thymus DNA (e.g., Pharmacia #27-4575-01)

To each of 12 reaction cocktails was added the appropriate amounts of dNTPs and ddNTPs as summarized below:

Cocktail	DGTP	dDATP	dCTP	TTP	ddGTP	ddATP	ddCTP	ddTTP
G-0	200μM	200μM	200μM	195μM	0	0	0	0
G-5	195μM	200μM	200μM	195μM	5	0	0	0
G-10	190μM	200μM	200μM	195μM	10	0	0	0
G-20	180μM	200μM	200μM	195μM	20	0	0	0
A-0	200μM	200μM	200μM	195μM	0	0	0	0
A-5	200μM	195μM	200μM	195μM	0	5	0	0
A-10	200μM	190μM	200μM	195μM	0	10	0	0
A-20	200μM	180μM	200μM	195μM	0	20	0	0
C-0	200μM	200μM	200μM	195μM	0	0	0	0
C-5	200μM	200μM	195μM	195μM	0	0	5	0
C-10	200μM	200μM	190μM	195μM	0	0	10	0
C-20	200μM	200μM	180μM	195μM	0	0	20	0
T-0	200μM	200μM	200μM	195μM	0	0	0	0
T-5	200μM	200μM	200μM	190μM	0	0	0	5
T-10	200μM	200μM	200μM	185μM	0	0	0	10
T-20	200μM	200μM	200μM	175μM	0	0	0	20

Incorporation was measured by adding 1μl of appropriately diluted bacterial extract (10,000 cpms) to 10μl of each polymerase cocktail. Polymerization reactions were conducted for 30 minutes at 72°C. The extension reactions were counted as described above.

Reactions that lacked enzyme were also set up along with sample incubations to determine “minimum cpms”(wash filters as above). To determine % activity as a function of ddNTP concentration, background (“minimum cpms” value) was first subtracted from each of the sample cpms. “Total cpms”, which are equivalent to 100% activity (0 ddNTPs), are determined by averaging the corrected cpms for the 4 reactions lacking ddNTPs (A-0, G-0, C-0, and T-0). Percent remaining activity was then calculated by dividing corrected sample cpms (with ddNTPs) by the corrected total cpms (average 0 ddNTPs).

Percent activity was plotted as a function of ddNTP concentration. I_{50%} values for each ddNTP (ddNTP concentration which inhibits nucleotide incorporation by 50%) were determined

for each mutant. Comparisons allowed the identification of mutants with improved ddNTP incorporation relative to wild type JDF-3.

Initial studies used purified enzymes, and $I_{50\%}$ values were determined from inhibition plots employing 40-160 μ M ddNTPs. The results in Table V show that mutants p8 (P41OL), p11 (P41OL), and p12(A485T) are inhibited by lower concentrations of ddNTPs than the parental exo^- JDF-3 polymerase. Greater sensitivity indicates that the mutants incorporate all four ddNTPs more efficiently than the original JDF-3 polymerase.

For enzymes which preferentially incorporate TTP over ddTTP (exo^- JDF-3, exo^- Pfu), the use of increasingly higher concentrations of ddTTP (80-160 μ M) and correspondingly lower concentrations of TTP (115-35 μ M), in combination with a constant amount of [3 H]TTP (5 μ M), leads to an increase in cpms incorporated with increasing ddNTP concentration. Therefore, in these initial experiments (where ddTTP >120 μ M), $I_{50\%}$ values for TTP are artificially high. While they can be used to compare ddTTP incorporation among different polymerase mutants, they can not be used to assess reduced/enhanced preference for ddTTP relative to ddCTP, ddGTP, or ddATP.

Table V $I_{50\%}$ Values for Purified JDF-3 and JDF-3 Mutants.

Purified Polymerase	Primary Mutation	$I_{50\%}$ Values (μ M)			
		ddATP	ddGTP	ddCTP	ddTTP
Exo $^-$ JDF-3	-	160	110	>160	>>160
Exo $^-$ Pfu	-	>160	>160	>160	>>160
JDF-3 mutant p8	P41OL	30	25	40	40
JDF-3 mutant p11	P41OL	30	30	60	>160
JDF-3 mutant p12	A485T	40	25	25	150

To allow a larger number of mutant clones to be screened, subsequent experiments employed bacterial extracts containing JDF-3 polymerase mutants. In addition, sensitivity was improved by using lower concentrations of each ddNTP inhibitor (5-20 μ M). The results in Table

VI demonstrate that all of the mutants selected from the primary filter screen exhibited improved incorporation of ddNTPs. Improvements in ddNTP incorporation were as high as >20-fold. All of the mutants containing a mutation at amino acid 408 (L408H/F), 410 (P410L), or 485 (A485T) (referred to as the “primary mutation”) exhibited reduced discrimination against all four ddNTPs. Most, but not all, mutants with the L408H/F primary mutation produced very similar $I_{50\%}$ values (<2-fold difference) for all four ddNTPs, indicating that base selectivity is diminished or absent.

Table VI. $I_{50\%}$ Values for JDF-3 Mutants (Bacterial Extracts).

JDF-3 mutant clones	Primary mutation	----- $I_{50\%}$ Values (μ M) -----			
		ddATP	ddGTP	ddCTP	ddTTP
Exo ⁻ JDF-3	-	>80	>80	>80	>80
1-1, 1-4, 1-18	L408H	8 to >20	4 to 5	6 to 13	5.5. to 10
1-25, 1-28, 1-29, 1-17	L408F	4.5 to >20	3.5 to 10	4 to 6.5	4 to 8
p8	P410L	18.5	12	9.5	>20
1-5, 1-6, 1-17	P410L	10 to >20	3.5 to 9	16.5 to >20	11 to >20
					5 to >20
1-41, 1-38, 1-37, 1-3, 1-19, 1-30, 1-27, 1,20 1-26, 1-32, 1-16, 1-12	Not determined	7 to >20	3.5 to 12	4 to >20	

Q. Sequencing with purified JDF-3 polymerase mutants.

i. Sequencing with radioactively labeled dideoxynucleotides

1 to 2 μ l of purified enzyme was substituted into the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham-Pharmacia #US79750). The samples were processed according to the manufacturer’s instructions using the control primer and template provided with the kit. Three microliters of each sequencing reaction were loaded onto a 6% acylamide-7M urea, 1x TBE CASTAWAY™ Precast gel (Stratagene catalog #s 401090 and 401094). When the bromophenol blue indicator dye reached the end of the gel, the gel was fixed, dried and exposed to film for 24-72 hours (Figure 6).

The results in Figure 6 show that clones p11 (panel D) and p8 (panel E) exhibit a dramatic improvement in the incorporation of all four ddNTPs compared to the parental #550 clone (panel B). Mutants p11 and p8 both contain the primary P410L mutation and an amino tag, but differ with respect to the number and types of ancillary mutations. Mutant p12 (panel C) produced a faint sequencing ladder, presumably due to the use of an insufficient amount of enzyme or the presence of ancillary mutations which reduce thermal stability. There is evidence of termination products in all lanes, suggesting an improvement in the incorporation of all four ddNTPs relative to the parental clone. Mutant p12 contains the primary mutation A485T in addition to ancillary mutations. In contrast to JDF-3 mutants identified here, the parental clone shows a strong preference to incorporate ddGTP, as evidenced both in primer extension (Figure 6) and ddNTP inhibition assays (Tables V and VI).

ii. Sequencing with a radioactively labeled primer and fluorescent dideoxynucleotides

Different DNA polymerases and polymerase mutants will exhibit varying degrees of discrimination against the dye moieties on the dideoxynucleotide analogs. An assessment of usage of dye-labeled dideoxynucleotide analogs by the JDF-3 polymerase mutants was carried out. The procedure used was as follows:

a. Primer Labeling

The sequencing primer SK was radioactively labeled with the KINACE-IT™ Kinasing Kit (Stratagene catalog #200390). The incubation reaction (40μl) contained the following components:

- 1X kinase buffer #1
- 0.75 μCi/μl γ -³³P ATP
- 0.375 u/μl T4 polynucleotide kinase
- 2.5 pmol/μl SK primer

The reaction was incubated at 37°C for 45 minutes. The primer was purified away from free nucleotides with a size exclusion matrix (NUC TRAP® Stratagene catalog number 400701).

b. Dye labeled-dideoxynucleotide : dNTP ratios

Fluorescent dideoxynucleotides were purchased from New England Nuclear (NEN):

R6G-ddATP NEN catalog number NEL-490

R110-ddTTP NEN catalog number NEL-495

TAMRA-ddUTP NEN catalog number NEL-472

ROX-ddCTP NEN catalog number NEL-477

Incorporation was measured using 3 different concentrations of dye labeled

dideoxynucleotides (ddNTPs) and a constant amount of deoxynucleotides (dNTPs;

2.14μM):

Condition 3) 1 : 1 (2.14μM each dNTP : 2.14μM dye-labeled ddNTP)

Condition 2) 1 : 0.1 (2.14μM each dNTP : 0.214μM dye-labeled ddNTP)

Condition 1) 1 : 0.01 (2.14μM each dNTP : 0.0214μM dye-labeled ddNTP)

c. Preparation of the DNA Sequencing Reaction Mixtures

Four polymerases were tested for utilization of dye-labeled ddNTPs, *exo*⁻ JDF-3 (#550 clone), Thermo Sequenase (4u/μl), JDF-3 P410L (clone p8 with ancillary mutations and an amino-terminal tag) and JDF-3 L408H (clone 1-1). A mixture containing the following reagents was assembled:

13.7μl H₂O

1μl labeled SK primer (2 pmol/μl)

1μl pBluescript KS (0.2μg/μl)

1µl polymerase (~1.5u/µl)

2µl 10X buffer (reaction buffer 1 for all but L408H which uses 1.5mM MgCl₂, buffer (see below)

10X Reaction Buffer 1

260mM Tris pH 9.5

65mM MgCl₂

10X 1.5mM MgCl₂ buffer

24 mM MgCl₂

260 mM Tris pH 9.5

2.5 µl of each dye-labeled ddNTP terminator (ddGTP, ddATP, ddTTP and

ddGTP was aliquotted separately into one of four tubes. 4.5µl of each polymerase

reaction was added to each of the four tubes, to give a final reaction volume of 7µl.

d. Cycle Sequencing Reactions

The samples were cycled in a RoboCycler®96 Temperature Cycler with

a Hot Top Assembly (Stratagene Catalog #400870 and #400894) using the following conditions:

1) 1 minute at 95°C

2) 1 minute at 95°C

3) 1 minute at 50°C

4) 2 minutes at 72°C

5) Repeat steps 2-4 thirty times.

4 µl of stop solution (95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) was added to each of the amplified reactions before heating them to 99°C for

five minutes. The samples were electrophoresed on a 6% CASTAWAY™ gel as described above. The gels were dried and then exposed to film for 72 hours (Figure 7).

The results of studies designed to assess utilization of dye-labeled ddNTPs by the different polymerase clones are shown in Figure 7. Clones p8 (panel C) and 1-1 (panel D) exhibited significantly improved incorporation of R6G-ddATP and R110-ddGTP, compared to the parental clone (panel A). Improvement was evidenced by the synthesis of sequencing ladders at .01x (1) and 0.1x (2) dye-ddNTP/dNTP ratios. Optimization of reaction conditions and/or dye moieties may be performed to realize improvements in the incorporation of ddTTP and ddCTP.

iii. Sequencing with double-mutant *exo⁻* JDF-3 DNA polymerase.

To verify that changes at residues 408, 410, and 485 were sufficient to improve ddNTP incorporation, individual mutations were introduced into the parental 550 (*JDF-3* *exo⁻* DNA polymerase) clone by site-directed mutagenesis. In addition, point mutations were combined to examine whether they resulted in further improvements in dideoxynucleotide incorporation over polymerases bearing single mutations.

DNA sequencing reactions consisting of 1x reaction buffer, 0.15pmol/μl long -20 primer, and 10ng/μg pBluescript KS were prepared as follows:

81μl	H ₂ O
9μl	-20 long primer (2pmol/μl)
6μl	pBluescript KS (0.2μg/μl)
**μl	polymerase
12μl	10X buffer (260mM Tris pH 9.5, 65mM MgCl ₂)

18μl of the cocktail listed above was aliquotted into the appropriate number of tubes (one per polymerase). Each polymerase (2 μl) was added to an aliquot of cocktail and the tubes

were mixed well. Each resulting polymerase mixture (4.5 µl) was then added to each of four tubes, already containing 0.06mM of one of the four ⁻³³P-dideoxynucleotides (ddATP, ddTTP, ddGTP or ddCTP; 1500Ci/mmol; 450µCi/ml) and 6mM each deoxynucleotide in a volume of 2.5µl.

The sequencing reactions were cycled in a ROBOCYCLER®96 temperature cycler with a Hot Top Assembly using the following conditions:

- 1) 1 minute at 95°C
- 2) 45 seconds at 95°C
- 3) 45 seconds at 60°C
- 4) 1.5 minutes at 72°C
- 5) Repeat steps 2-4 thirty times.

Stop solution (µl; 95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) was added to each reaction before heating to 99°C for five minutes. Each sample (4µl) was loaded onto a 6% acrylamide denaturing CastAway gel. The gel was run and treated as described previously.

Figure 8 shows that the P410L/A485T double mutant exhibits exceptionally even signals. Band uniformity was improved compared to mutant p8 (P410L mutation plus ancillary mutations that do not include A485T) and mutant A485T (data not shown). Mutant p8 exhibited a tendency to preferentially incorporate ddGTP and ddCTP in a sequence-dependent fashion. The optimal amount of enzyme may be higher than the quantity tested in this experiment. Sequence produced by the commercially available Family A DNA polymerase mutant, Thermo Sequenase, is shown in panel E.

iv. Ribonucleotide incorporation by JDF-3 polymerase mutants.

A primer annealed to single stranded DNA template was extended in a mixture containing all ribonucleotides or all deoxynucleotides with the mutant and progenitor polymerases.

M13mp18+ single stranded DNA was annealed to 95x molar excess of the 38mer primer by heating the mixture to 95°C and cooling slowly at room temperature.

38mer primer: 5' GGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGT 3'

Preliminary assays were carried out to determine what dilutions of enzyme would be necessary to examine the incorporation activity at non-maximal levels. The final assay solutions were composed as described below:

Ribonucleotide mixture

20 ng/μl annealed primer/template

1x Cloned Pfu buffer (Stratagene catalog #200532)

200μM each GTP, UTP, ATP

50μM CTP

1μM 5-³H CTP 20.2 Ci/mmol

0.05-0.3 units JDF-3 polymerase*

Deoxyribonucleotide mixture

20 ng/μl annealed primer template

1x Cloned Pfu buffer

200μM each dGTP, dATP, dCTP

50μM TTP (deoxyribonucleotide)

1μM Thymidine 5'-triphosphate, [methyl-³H] 20.5 Ci/mmol

0.05-0.3 units JDF-3 polymerase*

*Added separately

Nine microliters of the polymerase-free mixtures were placed in 0.2ml tubes before the polymerases were added. The samples were incubated at 72°C in a ROBOCYCLER®96 temperature cycler with Hot Top Assembly (Stratagene Catalog Nos. 400870 and 400894). The deoxyribonucleotide mixture was removed at 2 minutes and placed at approximately 2°C. The ribonucleotide mixture was incubated for 30 minutes. Seven microliters of the assay mixture were spotted onto DE81 filter circles (Whatmann) and dried prior to being washed three times in 2x SSC (0.3M NaCl, 0.03M sodium citrate) for five minutes each wash. The filters were rinsed twice in ethanol and allowed to dry before being quantified with a scintillation counter.

Background counts per minute (CPM) for the deoxyribonucleotide and the ribonucleotide reactions were subtracted from the respective averaged CPM value of duplicate samples for each enzyme. The background-corrected ribonucleotide CPM value was divided by the background-corrected deoxyribonucleotide CPM value (Figure 9).

Polymerase	Ratio NTP/dNTP	Relative to JDF-3
		550
JDF-3 550	0.000165162	1
JDF-3 L408H	0.041087258	249
JDF-3 L408F	0.051703924	313
JDF-3 A485T	0.007628583	46

v. Ribonucleotide sequencing with JDF-3 polymerase mutants.

Ribonucleotides incorporated into a deoxyribonucleotide polymer are susceptible to alkali hydrolysis which can produce a sub-population of polymer lengths. When labeled primer

is extended in the presence of a particular ribonucleotide base (for example ATP) and the four deoxyribonucleotide bases, the fragments resulting from alkali hydrolysis create a population of different lengths, which correspond to all the possible positions where ATP was incorporated. When those fragments are size separated, their migration pattern, with respect to other ribonucleotide base (CTP, UTP and GTP) hydrolysis products allows the template sequence to be read. As described previously, most DNA polymerases discriminate against non-conventional deoxynucleotides. A subset of the JDF-3 DNA polymerase mutants which allow improved uptake of the unconventional dideoxynucleotides also show improved tolerance for ribonucleotide incorporation.

100ng of the 38mer primer was kinased with γ -³³P according to the instructions in the KINACE-IT™ Kinasing Kit (Stratagene catalog #300390).

38mer primer: 5' GGTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGT 3'

The labeled oligonucleotide was purified from contaminating free nucleotides with a NUC TRAP® Probe Purification Column (Statagene catalog #400701) in 10T.1E (10mM Tris pH 8.0, 0.1mM EDTA). Labeled oligonucleotide (~7 picomoles) was annealed to 0.09 pmoles M13mp18+ by heating to 95°C then cooling to room temperature in the presence of 0.32mM MgCl₂.

Extension components

0.054 pM annealed primer/template

200 □Meach dNTP

1x cPfu DNA polymerase buffer (Stratagene catalog #200532)

4-200 ATP*

0.1-5 Units JDF-3 polymerase*

*Added separately

Eight microliters of a cocktail containing the first three components listed above were aliquoted into a 0.2ml tube. 1µl of polymerase and 1 µl of 2mM, 0.2mM or 0.4mM ATP were added and the reaction was incubated at 72°C for 15 minutes. The reaction volume was brought to 100µl with 1x cPfu polymerase buffer and transferred to a 1.5ml tube. After heating the reactions in the presence of 70mM NaOH for 15 minutes at 100°C, the reaction was neutralized with 70mM HCl and precipitated through the addition of 10µl 3M sodium acetate and 327.5µl of ethanol. The samples were microcentrifuged for 30 minutes at 14krpm before the supernatant was removed and the pellet washed in 80% ethanol. After vacuum drying, the samples were resuspended in 5µl of sequencing stop solution (95% formamide, 20mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol FF) and 2.5µl was loaded on a 6% acylamide-7M urea, 1x TBE CASTAWAY™ Precast gel (Stratagene catalog numbers 401090 and 401094). The gels were run at 50 watts until the bromophenol blue dye migrated past the bottom of the gel after which the gel was fixed, dried and exposed to film for 72 hours.

Sequencing ladders for JDF-3 550 (wild-type nucleotide incorporation) and all the mutants tested were visible at the 200µM and 20µM ATP level. At the 4µM level, only the L408H and L408F mutants produced ladders (data not shown).

vi. Sequencing with dye-dideoxynucleotide terminators

Primer was extended in the presence of FAM ddCTP (NENNEL481). The sequence reactions were purified and run on an ABI 370.

Reaction conditions for cycle-sequencing were as described below:

1X cPFU buffer, 200 ng pBluescript II KS plasmid, 3 pmole T7 primer, 0.23 mM dCTP, 0.23 mM dATP, 0.23 mM dTTP, 0.23 mM dGTP with 0.046 mM FAM ddCTP. The samples

were cycled in a Perkin-Elmer cycler in 10 µl volumes for 25 cycles of the temperatures and times described below:

95°C	30s
55°C	30s
72°C	2 min

The samples were purified using CentriSep columns according to the manufacturer's instructions. After drying, the samples were resuspended in 3 µl of a loading dye comprised of 66.7% deionized formamide, 16.7 mg/ml Blue Dextran, and 8.3 mM EDTA. Samples were heated at 95°C for three minutes and loaded on a 5% LongRangen gel in an ABI PRISM 377 DNA sequencer.

Data was processed in Gene Scan 2.1.

EXAMPLE 2.

Labeling of DNA.

The modified DNA polymerases of the invention are applicable to labeling of DNA. It is known to those skilled in the art that there are several means by which to label DNA, including the incorporation of radiolabeled nucleotides. One such common means is by random priming, which enables one of skill in the art to generate labeled DNA fragments, typically about 50 to about 1000 bases long. The procedure described herein are adapted from F. Ausubel et al., Short Protocols in Molecular Biology, Third Edition, John Wiley and Sons, Inc., 1995.

As a first step toward random priming DNA, a reaction mix containing 2.5 microliters 0.5 mM 3dNTP (dCTP, dGTP, TTP, each at 0.5 mM), 50 µCi [⁻³²P]dATP, 1 microliter of 3 to 8 units/microliter DNA polymerase in 50 mM Tris-HCl, pH 7.5, 10 mM MgCl₂, 1 mM dithiothreitol, 0.05 mg/ml bovine serum albumin is prepared in a total volume of 11 microliters and incubated on ice. Next, about 30 to about 100 ng of DNA is mixed with about with 1 to 5 µg of random hexanucleotides in 14 microliters and boiled for 2 to 3 minutes and then placed on ice.

The 11 microliter reaction mix is then added to the DNA/random hexamer mix, and the random priming reaction is incubated over 10 minutes to as much as 4 hours at room temperature. To stop the reaction, 1 microliter 0.5 M EDTA, 3 microliters 10 mg/ml tRNA, and 100 microliters 10 mM Tris-HCl, pH 7.4 is added and the mixture is extracted with phenol. The labeled DNA is then separated from unincorporated radioactive precursors by chromatography.

R. Gel Assay for Dye-dideoxynucleotide Incorporation.

A labeled oligonucleotide duplex was extended with a mixture of dideoxynucleotides and dye-dideoxynucleotides. When the duplex was separated on a denaturing 20% Acrylamide/7 M urea gel, labeled oligonucleotides terminated with a dideoxynucleotide could be resolved from oligonucleotides terminated with dye-deoxynucleotides.

Oligonucleotides:

259C	³² P-TAACGTTGGGGGGGGGCA→
258C	TGCAACCCCCCCCCGTAT

The 5' end of 259C was labeled and purified as described in Section Q.ii.a except that ³²Pγ-ATP was used. The labeled oligonucleotide 259C was at a concentration of approximately 0.7 ng/μl. The complimentary oligonucleotide (258C) was added as an equal concentration, heated to 95°C for three minutes, 50°C for 5 minutes and room temperature for 20 minutes. Heat killed lysates of the relevant mutants were prepared as described in Example section C. The reactions were incubated in a 5 μl volume composed of 30 mM Tris pH 8.0 and 3 mM MgCl₂ with a nucleotide mixture totaling 0.1 mM. The ratio of ddTTP to FLU ddUTP or ROXddUTP was 10:1. The dimer was present at a concentration of 1.2 picomoles and 0.5 μl of enzyme or crude lysate or purified enzyme was added to the reaction before incubation at 50°C in the

RoboCycler® Gradient 96 Temperature Cycler with Hot Top. The samples were incubated for 20s before 3 µl of a formamide based loading dye was added and the samples were heat-denatured at 95°C for 3 minutes then loaded onto a 20% acrylamide/7 M urea gel and subjected to electrophoresis at a constant 60 watts. The gel was exposed to X-ray film and the film was analyzed in the EagleEye® Eagle Sight software package.

References for Table I

1. Joyce, C.M., Kelley, W.S. and Grindley N.D.F. (1982) J. Biol. Chem. 257, 1958-1964.
2. Lopes, P. Martinez, S., Diaz, A. Espinosa, M. And Lacks, S.A. (1989) J. Biol. Chem. 264 , 4255-4263.
3. Lawyer, F.C., Stoffel, S., Saiki, R.K., Myambo, K. Drummond, R. and Gelfand, D.H. (1989) J. Biol. Chem. 264, 6427-6437.
4. Akhmetzjanov, A.A. and Vakhitov, V.A. (1992) Nucl. Acids Res. 20, 5839.
5. Leavitt, M.C. and Ito, J. (1989) Proc. Acad. Sci. U.S.A. 86, 4465-4469.
6. Dunn, J.J. and Studier, F.W. (1983) J. Mol. Biol. 166, 477-535.
7. Scarlato, V. And Gargano, S. (1992) Gene 118, 109-113.
8. Rådén, B. And Rutberg, L. (1984) J. Virol. 52, 9-15.
9. Foury, F. (1989) J. Biol. Chem. 264, 20552-20560.
10. Ito, J. And Braithwaite, D.K. (1990) Nucl. Acids Res. 18, 6716.
11. Blanco, L. Bernad, A. And Salas, M. (1991) Nucl. Acids res. 19, 955.
12. Hahn, S. And Rüger, W, (1989) Nucl. Acids Res. 17, 6729.
13. Hollingsworth, H.C. and Nossal, N.G. (1991) J. Biol. Chem. 266, 1888-1897.
14. Kaliman, A.V., Krutilina, A.I., Kryukov, V.M. and Bayev, A.A. (1986) FEBS Lett. 195, 61-64.

15. Iwasaki, H. Ishino, Y., Toh, H. Nakata, A. and Shinagawa, H. (1991) *Mol. Gen Genet.* 226, 24-33.
16. Jung, G., Leavitt, M.C., Hsieh, J.-C. and Ito, J. (1987) *Proc. Natl. Acad. Sci. U.S.A.* 84, 8287-8291.
17. Savilahti, H. And Bamford D.H. (1987) *Gene* 57, 121-130.
18. Yoshikawa, H. And Ito, J. (1982) *Gene* 17, 323-335.
19. Matsumoto, K., Takano, H., Kim, C.I. and Hirokawa, H. (1989) *Gene* 84, 247-255.
20. Spicer, E.K., Rush, J. Fung, C., Reha-Krantz, L.J., Karam, J.D. and Konigsberg, W.H. (1988) *J. Biol. Chem.* 263, 7478-7486.
21. Perler, F.B., Comb, D.G., Jack, W.E., Moran, L.S., Qiang, B., Kucera, R.B., Benner, J., Slatko, B.E., Nwankwo, D.O., Hempstead, S.K., Carlow, C.K.S. and Jannasch, H. (1992) *Proc. Natl. Acad. Sci. USA* 89, 5577-5581.
22. Mathur, E.J., Adams, M.W., Callen, W.N. and Cline, J.M. (1991) *Nucleic. Acids Res.* 19, 6952.
23. Pisani, F.W., De Martino, C. and Rossi, M. (1992) *Nucl. Acids Res.* 20, 2711 - 2716.
24. Wong S., W. Wahl, A.F., Yuan, P.-M., Arai, N., Pearson, B.E., Arai, K, -i., Korn, D., Hunkapiller, M. W. and Wang, T.S.-F. (1988) *EMBO J.* 7, 37-47.
25. Pizzagalli, A., Valsasnini, P., Plevani, P. and Lucchini, G. (1988) *Proc. Natl. Acad. Sci. U.S.A.* 85, 3772-3776.
26. Damagnez, V., Tillit, J., deRecondo, A.-M. and Baldacci, G. (1991) *Mol. Gen. Genet.* 226, 182-189.
27. Hirose, F., Yamaguchi, M. Nishida, Y., Masutani, M., Miyazawa, H., Hanaoka, F. and Matsukage, A. (1991) *Nucl. Acids Res.* 19, 4991-4998.

28. Leegwater, P.A.J., Strating, M., Murphy, N.B., Kooy, R.F., van der Vliet, P.C. and Overdulse, J.P. (1991) *Nucl. Acids Res.* 19, 6441-6447.
29. Chung, D.W., Zhang, J., Tan C.-K., Davie, E.W., So, A.G. and Downey, K.M. (1991) *Proc. Natl. Acad. Sci. USA* 88, 11197-11201.
30. Yang, C.-L., Chang, L.S., Zhang, P., Hao, H., Zhu, L., Tommey, N.L. and Lee, M.Y.W.T. (1992) *Nucl. Acids Res.* 20, 735-745.
31. Zhang, J. Chung, D.W., Tan, C.-K., Downey, K.M., Davie, E.W. and So, A.G. (1991) *Biochemistry* 30, 11742-11750.
32. Morrison, A. and Sugino, A. (1992) *Nucl. Acids Res.* 20, 375.
33. Pignéde, G., Bouvier, D., deRecondo, A.-M. And Baldacci, G. (1991) *J. Mol. Biol.* 222, 209-218.
34. Ridley, R.G., White, J.H., McAleese, S.M., Gorman, M., Alano, P., deVies, E. and Kilbey, B.J. (1991) *Nucl. Acids Res.* 19, 6731-6736.
35. Morrison, A., Araki, H., Clark, A.B., Hamatake, R.K. and Sugino, A. (1990) *Cell* 62, 1143-1151.
36. Morrison, A., Christensen, R.B., Alley, J., Beck, A.K., Bernstine, E.G., Lemontt, J.F. and Lawrence, C.W. (1989) *J. Bacteriol.* 171, 5659-5667.
37. Gibbs, J.S., Chiou, H.C., Hall, J.D., Mount, D.W., Retondo, M.J., Weller, S.K. and Coen, D.M. (1985) *Proc. Natl. Acad. Sci. U.S.A.* 82, 7969-7973.
38. Telford, E.A., Watson, M.S., McBride, K. and Davison, A.J. (1992) *Virology* 189, 304-316.
39. Davison, A.J. and Scott, J.E. (1986) *J. Gen. Virol.* 67, 1759-1816.
40. Baer, R., Bankier, A.T. Biggin, M.D., Deininger, P.L., Farrell, P.J., Gibson, T.J., Hatfull, G., Hudson, G.S., Satchwell, S.C., Séguin, C., Tuffnell, P.S. and Barrell, B.G. (1984) *Nature* 310, 207-211.

41. Albrecht, J.-C. and Fleckenstein, B. (1990) *Virology* 174, 533-542.
42. Kouzarides, T. Bankier, A.T. , Satchwell, S.C., Weston, K., Tomlinson, P. and Barrell, B.G. (1987) *J. Virol*, 61, 125-133.
43. Elliott, R., Clark, C. Jaquish, D. and Spector, D.H. (1991) *Virology* 185, 169-186.
44. Teo, I.A., Griffin, B.E. and Jones, M.D. (1991) *J. Virol.* 65, 4670-4680.
45. Davison, A.J. (1992) *Virology* 186, 9-14.
46. Grabherr, R., Strasser, P. and Van Etten, J.L. (1992) *Virology* 188, 721-731.
47. Binns, M. M., Stenzler, L. Tomley, F.M., Campbell, J. and Brounsnell, M.E.G. (1987) *Nucl. Acids Res.* 15, 6563-6573.
48. Earl P.L., Jones, E.V. and Moss, B. (1986) *Prov. Natl. Acad. Sci. U.S.A.* 83, 3659-3663.
49. Mustafa, A. And Yuen, L. (1991) *DNA Seq.* 2, 39-45.
50. Tomalski, M.D., Wu, J. and Miller, L.K. (1988) *Virology* 167, 591-600.
51. Bjornson, R.M. and Rohrmann, G.F. (1992) *J. Gen. Virol* 73, 1499-1504.
52. Gingeras, T.R., Sciaky, D., Gelinas, R.E., Bing-Dong, J., Yen, C.E., Kelly, M.M., Bullock, P.A. Parsons, B.L., O'Neill. K.E. and Roberts, R.J. (1982) *J. Biol. Chem*, 257, 13475-13491.
53. Engler, J.A., Hoppe, M.S. and van Bree, M.P. (1983) *Gene* 21, 145-159.
54. Shu, L., Hing, J.S., Wei, Y.-f. and Engler, J.A., (1986) *Gene* 46, 187-195.
55. Paillard, M., Sederoff, R.R. and Levings, C.S. III (1985) *EMBRO J.* 4, 1125-1128.
56. Chan, B.S.-S., Court, D.A., Vierula, P.J. and Bertrand, H. (1991) *Curr. Genet.* 20, 225-237.
57. Kempken, F., Meinhardt, F. and Esser, K. (1989) *Mol. Gen. Genet*, 218, 623-530.
58. Oester, B. And Tudzynski, P. (1989) *Mol. Gen. Genet.* 217, 132-140.
59. Court D.A. and Bertrand, H. (1992) *Curr. Genet.* 22, 385-397.
60. Robison, M.M., Royer, J.C. and Horgen, P.A. (1991) *Curr. Genet.* 19, 495-502.

61. Stark, M.J.R., Mileham, A.J., Romanos, M.A. and Boyd, A. (1994) Nucl. Acids Res. 12, 6011-6030.
62. Tommasino, M. Ricci, S. and Galeotti, C.L. (1988) Nucl. Acids Res. 16, 5863-5878.
63. Hishinuma, F. and Hirai, K. (1991) J. Gen. Genet. 226, 97-106.
64. Hopfner, K.P. et al. (1999) Proc. Natl. Acad. Sci. U.S.A. 96, 3600-3605.
65. Niehaus, F. et al. (1997) Gene 204, 153-158.
66. Tagaki et al. (1997) Appl. Environ. Microbiol. 63, 4504-4510.
67. Datukishvili, N. et al. (1996) Gene 177, 271-273.
68. Southworth, M.W. et al. (1996) Proc. Natl. Acad. Sci. U.S.A. 93, 5281-5285.
69. Uemori, T. et al. (1995) J. Bacteriol. 177, 2164-2177.
70. Konisky, J. et al. (1994) J. Bacteriol. 176, 6402-6403.
71. Zhao (1999) Structure Fold Des. 7, 1189.

OTHER EMBODIMENTS

Other embodiments will be evident to those of skill in the art. It should be understood that the foregoing detailed description is provided for clarity only and is merely exemplary. The spirit and scope of the present invention are not limited to the above examples, but are encompassed by the following claims.

CLAIMS

1. A purified thermostable DNA polymerase having an amino acid sequence presented in SEQ ID NO: 2 from residue 1 to 776.
2. The polymerase of claim 1 that is isolated from *Thermococcus* species JDF-3.
3. The polymerase of claim 1 that is isolated from a recombinant organism transformed with a vector that codes for the expression of *Thermococcus* species JDF-3 DNA polymerase.
4. A recombinant vector comprising the nucleotide sequence presented in SEQ ID NO: 1.
5. An isolated recombinant polypeptide comprising the amino acid sequence of SEQ ID NO: 2.
6. An isolated recombinant DNA polymerase from *Thermococcus* species JDF-3 that is 3' to 5' exonuclease deficient.
7. The isolated recombinant DNA polymerase of claim 6, wherein said polymerase has a dual mutation comprising a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2; and a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.
8. The isolated recombinant DNA polymerase of claim 6 that has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2 or a glutamic acid to alanine mutation at the amino acid corresponding to E143 of SEQ ID NO: 2.
9. The isolated recombinant DNA polymerase of claim 6 that has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2 and a glutamic acid to alanine mutation at the amino acid corresponding to E143 of SEQ ID NO: 2.
10. An isolated recombinant DNA polymerase having reduced discrimination against non-conventional nucleotides.
11. The DNA polymerase of claim 6 or 10 that is a Family B DNA polymerase.
12. The DNA polymerase of claim 6 or 10 wherein said DNA polymerase further comprises a mutation selected from the group consisting of: a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2; a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2; a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2; and an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2.
13. The DNA polymerase of claim 12 wherein said polymerase having said alanine to threonine mutation at said site corresponding to A485 of SEQ ID NO: 2 further comprises a mutation selected from the group consisting of: a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2; a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2; a serine to proline mutation at a site corresponding to

S345 of SEQ ID NO: 2; and a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

14. The DNA polymerase of claim 6 or 10 that has reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides and conjugated nucleotides.

15. The DNA polymerase of claim 14 wherein said conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

16. An isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO: 2, or a mutation at a site corresponding to L408, S345 or P410 of SEQ ID NO: 2, wherein said DNA polymerase has reduced discrimination against non-conventional nucleotides relative to the wild-type form of that polymerase.

17. The polymerase of claim 16 that is 3' to 5' exonuclease deficient.

18. The polymerase of claim 17 that has a mutation at an amino acid corresponding to D141 or E143 of SEQ ID NO: 2.

19. The polymerase of claim 17 that has an aspartic acid to threonine or alanine mutation at a site corresponding to D141 of SEQ ID NO: 2.

20. The polymerase of claim 17 that has a glutamic acid to alanine mutation at a site corresponding to E143 of SEQ ID NO: 2.

21. The polymerase of claim 20 that has an aspartic acid to threonine or alanine mutation at the amino acid corresponding to D141 of SEQ ID NO: 2.

22. The polymerase of claim 16 that is thermostable.

23. The polymerase of claim 16 that is archaeal.

24. The polymerase of claim 16 wherein said DNA polymerase comprises a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

25. The polymerase of claim 16 wherein said DNA polymerase comprises a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

26. The polymerase of claim 16 wherein said DNA polymerase comprises a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

27. The polymerase of claim 16 wherein said DNA polymerase comprises a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2, wherein said polymerase may further comprise a mutation at a site corresponding to T604 of SEQ ID NO: 2.

28. The polymerase of claim 16, wherein said DNA polymerase comprises a tyrosine to cysteine mutation at a site corresponding to Y497 of SEQ ID NO: 2, wherein said polymerase may further comprise an isoleucine to valine mutation at a site corresponding to I630 of SEQ ID NO: 2.

29. The polymerase of claim 16, wherein said DNA polymerase comprises a glutamic acid to lysine mutation at a site corresponding to E645 of SEQ ID NO: 2.

30. The polymerase of claim 16, wherein said DNA polymerase comprises a glutamic acid to lysine mutation at a site corresponding to E578 of SEQ ID NO: 2, wherein said polymerase may further comprise an arginine to methionine mutation at a site corresponding to R465 of SEQ ID NO: 2.

31. The polymerase of claim 16, wherein said DNA polymerase comprises a leucine to glutamine mutation at a site corresponding to L396 of SEQ ID NO: 2, wherein said polymerase further comprises a mutation at a site corresponding to V401, N424, P569, E617, or V640 of SEQ ID NO: 2.

32. The polymerase of claim 16, wherein said DNA polymerase comprises a serine to asparagine mutation at a site corresponding to S651 of SEQ ID NO: 2.

33. The polymerase of claim 16, wherein said DNA polymerase comprises a leucine to proline mutation at a site corresponding to L396 of SEQ ID NO: 2, wherein said polymerase may further comprise a mutation at a site corresponding to E459 of SEQ ID NO: 2.

34. The polymerase of claim 16, wherein said DNA polymerase comprises a leucine to proline mutation at a site corresponding to L456 of SEQ ID NO: 2, wherein said polymerase may further comprise a mutation at a site corresponding to E658 of SEQ ID NO: 2.

35. The polymerase of claim 16, wherein said DNA polymerase comprises a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2, wherein said polymerase may further comprise a mutation at a site corresponding to V437, or L478 of SEQ ID NO: 2.

36. The polymerase of claim 16 wherein said DNA polymerase comprises an tyrosine to asparagine mutation at a site corresponding to Y496 of SEQ ID NO: 2.

37. The polymerase of claim 16 wherein said DNA polymerase comprises an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2.

38. The polymerase of claim 37 comprising a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

39. The polymerase of claim 37 comprising a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

40. The polymerase of claim 37 comprising a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

41. The polymerase of claim 16, having reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides and conjugated nucleotides.

42. The polymerase of claim 41 wherein said conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

43. The polymerase of claim 10 or 16 further comprising a mutation at an amino acid residue in the polymerase that corresponds to a mutation selected from the group consisting of: a Y to V mutation at amino acid 409 of SEQ ID NO:2; an A to C, S, L, I, F, or V mutation at amino acid 485 of SEQ ID NO: 2; a Y to S mutation at amino acid 494 of SEQ ID NO: 2; a Y to L mutation at amino acid 496 of SEQ ID NO: 2; and an A to Y mutation at amino acid 490 of SEQ ID NO: 2.

44. The polymerase of claim 10 or 16 further comprising a mutation at an amino acid of the polymerase corresponding to one of amino acids 483 to 496, inclusive, of SEQ ID NO: 2.

45. The polymerase of claim 44 wherein said mutation is at an amino acid of the polymerase corresponding to one of amino acids 485, 490, 494, or 496 of SEQ ID NO: 2.

46. An isolated recombinant Family B DNA polymerase comprising an alanine to threonine mutation at an amino acid corresponding to A485T of SEQ ID NO: 2 and at least one substitution in the polymerase of an amino acid corresponding to L408, Y409, S345 or P410 respectively, of SEQ ID NO: 2.

47. An isolated recombinant Family B DNA polymerase comprising an amino acid other than A at an amino acid of the polymerase corresponding to A485 of SEQ ID NO: 2, and at least one substitution in the polymerase of an amino acid corresponding to L408, Y409, S345 or P410, respectively, of SEQ ID NO: 2.

48. A recombinant vector comprising a nucleic acid sequence encoding the DNA polymerase of any one of claims 1, 5, 6, 10, 16, 46 or 47.

49. A method of labeling a complementary strand of DNA, which method comprises the step of:

contacting a template DNA molecule with:

a recombinant Family B DNA polymerase of claim 10; and

a non-conventional nucleotide under conditions and for a time sufficient to permit said DNA polymerase to synthesize a complementary DNA strand and to incorporate said non-conventional nucleotide into said complementary DNA strand.

50. A method of labeling a complementary strand of DNA, which method comprises the step of:

contacting a template DNA molecule with:

a recombinant Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 or S345 of SEQ ID NO: 2, wherein said DNA polymerase has reduced discrimination against non-conventional nucleotides; and

a non-conventional nucleotide under conditions and for a time sufficient to permit said DNA polymerase to synthesize a complementary DNA strand and to incorporate said non-conventional nucleotide into said complementary DNA strand.

51. The method of claim 50 wherein said recombinant Family B DNA polymerase is 3'-5' exonuclease deficient.

52. The method of any one of claims 49-51 wherein said recombinant Family B polymerase comprises a leucine to histidine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

53. The method of any one of claims 49-51 wherein said recombinant Family B polymerase comprises a leucine to phenylalanine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

54. The method of any one of claims 49-51 wherein said recombinant Family B polymerase comprises a proline to leucine mutation at a site corresponding to amino acid P410 of SEQ ID NO: 2.

55. The method of any one of claims 49-51 wherein said recombinant Family B polymerase comprises an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2.

56. The method of claim 55 wherein said recombinant Family B polymerase comprises a leucine to histidine mutation at an amino acid corresponding to L408 of SEQ ID NO: 2.

57. The method of claim 55 wherein said recombinant Family B polymerase comprises a leucine to phenylalanine mutation at an amino acid corresponding to L408 of SEQ ID NO: 2.

58. The method of claim 55 wherein said recombinant Family B polymerase comprises a proline to leucine mutation at an amino acid corresponding to P410 of SEQ ID NO: 2.

59. The method of claim 55 wherein said recombinant Family B polymerase comprises a serine to proline mutation at an amino acid corresponding to S345 of SEQ ID NO: 2.

60. The method of claim 55, wherein said recombinant Family B polymerase has a dual mutation comprising a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2; and a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

61. The method of any one of claims 49-51 wherein said recombinant Family B polymerase has reduced discrimination against a non-conventional nucleotide selected from the group consisting of: dideoxynucleotides, ribonucleotides, and conjugated nucleotides.

62. The method of claim 61 wherein said conjugated nucleotide is selected from the group consisting of radiolabeled nucleotides, fluorescently labeled nucleotides, biotin labeled nucleotides, chemiluminescently labeled nucleotides and quantum dot labeled nucleotides.

63. A method of sequencing DNA comprising the steps of:

contacting a template DNA strand with:

a sequencing primer;

a recombinant Family B DNA polymerase of claim 9; and

a chain-terminating nucleotide analog, under conditions that permit said DNA polymerase to synthesize a complementary DNA strand and to incorporate nucleotides into the synthesized complementary DNA strand, wherein incorporation of a chain-terminating nucleotide analog results in the termination of chain elongation, such that the nucleotide sequence of said DNA strand is determined.

64. A method of sequencing DNA comprising the steps of:

contacting a DNA strand with:

a sequencing primer;

a recombinant Family B DNA polymerase comprising an alanine to threonine mutation at a site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 or S345 of SEQ ID NO: 2, wherein said DNA polymerase has reduced discrimination against non-conventional nucleotides; and

a chain-terminating nucleotide analog, under conditions that permit said DNA polymerase to synthesize a complementary DNA strand and to incorporate nucleotides into the synthesized complementary DNA strand, wherein incorporation of a chain-terminating nucleotide analog results in the termination of chain elongation, such that the nucleotide sequence of said DNA strand is determined.

65. The method of claim 64 wherein said recombinant Family B polymerase is deficient in 3' to 5' exonuclease activity.

66. The method of any one of claims 63-65 wherein said recombinant Family B polymerase has a leucine to histidine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

67. The method of any one of claims 63-65 wherein said recombinant Family B polymerase has a leucine to phenylalanine mutation at a site corresponding to amino acid L408 of SEQ ID NO: 2.

68. The method of any one of claims 63-65 wherein said recombinant Family B polymerase has a proline to leucine mutation at a site corresponding to amino acid P410 of SEQ ID NO: 2.

69. The method of any one of claims 63-65 wherein said recombinant Family B polymerase has an alanine to threonine mutation at a site corresponding to amino acid A485 of SEQ ID NO: 2.

70. The method of claim 69 wherein said recombinant Family B polymerase has a leucine to histidine mutation at a site corresponding to L408 of SEQ ID NO: 2.

71. The method of claim 69 wherein said recombinant Family B polymerase has a leucine to phenylalanine mutation at a site corresponding to L408 of SEQ ID NO: 2.

72. The method of claim 69 wherein said recombinant Family B polymerase has a proline to leucine mutation at a site corresponding to P410 of SEQ ID NO: 2.

73. The method of claim 69 wherein said recombinant Family B polymerase has a serine to proline mutation at a site corresponding to S345 of SEQ ID NO: 2.

74. The method of any one of claims 63-65 wherein said chain-terminating nucleotide analog is a dideoxynucleotide.

75. The method of claim 74 wherein said dideoxynucleotide is detectably labeled.

76. The method of claim 75 wherein said dideoxynucleotide is fluorescently labeled.

77. The method of claim 76 wherein said dideoxynucleotide is labeled with a moiety selected from the group consisting of fluorescein and rhodamine.

78. A kit for performing the method of claim 49, 50, 51, 63, or 64.

79. A method of making a purified thermostable DNA polymerase having an amino acid sequence presented in SEQ ID NO: 2 from residue 1 to 776, comprising culturing a host cell containing the nucleic acid sequence presented in SEQ ID NO:1 under conditions which permit production of said DNA polymerase.

80. A method of making a recombinant DNA polymerase of *Thermococcus* species JDF-3 that is 3' to 5' exonuclease deficient, comprising culturing a host cell containing a nucleic acid sequence encoding said polymerase under conditions which permit production of said DNA polymerase.

81. A method of making a recombinant DNA polymerase having reduced discrimination against non-conventional nucleotides, comprising culturing a host cell containing a nucleic acid sequence encoding said polymerase under conditions which permit production of said DNA polymerase.

82. A method of making a recombinant Family B DNA polymerase comprising an alanine to threonine mutation at the site corresponding to A485 of SEQ ID NO: 2 or a mutation at a site corresponding to L408 or P410 or S345 of SEQ ID NO: 2, wherein said DNA polymerase has reduced discrimination against non-conventional nucleotides relative to the wild-type form of

that polymerase, comprising culturing a host cell containing a nucleic acid sequence encoding said polymerase under conditions which permit production of said DNA polymerase.

83. The method of claim 79, 80, 81, or 82, wherein said host cell is *E. Coli*.

84. The method of claim 79, 80, 81, or 82, wherein said host cell is *Thermococcus*.

FIG. 1.

JDF-3 DNA polymerase nucleotide sequence: 2331 nucleotides (SEQ ID NO: 1)

ATGATCCTTGACGTTGATTACATCACCGAGAATGGAAAGCCCGTCATCAGGGTCTTCAAGAAGGAGAACGG
CGAGTTCAGGATTGAATACGACCGCGAGTTCGAGCCCTACTTCTACGCGCTCCTCAGGGACGACTCTGCCA
TCGAAGAAATCAAAAAGATAACCGCGGAGAGGCACGGCAGGGTCGTTAAGGTTAAGCGCGCGGAGAAGGTG
AAGAAAAAGTTCTCGGCAGGTCTGTGGAGGTCTGGGTCTCTACTTCACGCACCCGCGAGGACGTTCGGGC
AATCCGCGACAAAATAAGGAAGCACCCCGCGGTTCATCGACATCTACGAGTACGACATACCCTTCGCCAAGC
GCTACCTCATAGACAAGGGCCTAATCCCGATGGAAGGTGAGGAAGAGCTTAAACTCATGTCCTTCGACATC
GAGACGCTCTACCACGAGGGAGAAGAGTTTGGAAACCGGGCCGATTCTGATGATAAGCTACGCCGATGAAAG
CGAGGCGCGCGTGATAACCTGGAAGAAGATCGACCTTCCTTACGTTGAGGTTGTCTCCACCGAGAAGGAGA
TGATTAAGCGCTTCTTGAGGGTCGTTAAGGAGAAGGACCCGGACGTGCTGATAACATAACAACGGCGACAAC
TTCGACTTCGCCTACCTGAAAAAGCGCTGTGAGAAGCTTGGCGTGAGCTTTACCCTCGGGAGGGACGGGAG
CGAGCCGAAGATACAGCGCATGGGGGACAGGTTTGGCGTCGAGGTGAAGGGCAGGGTACACTTCGACCTTT
ATCCAGTCATAAGGCGCACCATAAACCTCCCGACCTACACCCTTGAGGCTGTATACGAGGCGGTTTTTCGGC
AAGCCCCAAGGAGAAGGTCTACGCCGAGGAGATAGCCACCGCTGGGAGACCGGCGAGGGGCTTGAGAGGGT
CGCGCGCTACTCGATGGAGGACGCGAGGGTTACCTACGAGCTTGGCAGGGAGTTCTTCCCGATGGAGGCCC
AGCTTTCCAGGCTCATCGGCCAAGGCCTCTGGGACGTTTCCCGCTCCAGCACCGGCAACCTCGTCGAGTGG
TTCCTCCTAAGGAAGGCCTACGAGAGGAACGAACCTCGCTCCCAACAAGCCCGACGAGAGGGGAGCTGGCGAG
GAGAAGGGGGGGCTACgCCGGTGGCTACGTCAAGGAGCCGGAGCGGGGACTGTGGGACAATATCGTGTATC
TAGACTTTCTGTAGTCTCTACCCTTCAATCATAATCACCCACAACGTCTCGCCAGATACGCTCAACCGCGAG
GGGTGTAGGAGCTACGACGTTGCCCGGAGGTCGGTCACAAGTTCTGCAAGGACTTCCCCGGCTTCATTCC
GAGCCTGCTCGGAAACCTGCTGGAGGAAAGGCAGAAGATAAAGAGGAAGATGAAGGCAACTCTCGACCCGC
TGGAGAAGAATCTCCTCGATTACAGGCAACGCGCCATCAAGATTCTCGCCAACAGCTACTACGGCTACTAC
GGCTATGCCAGGGCAAGATGGTACTGCAGGGAGTGCGCCGAGAGCGTTACGGCATGGGGAAGGGAGTACAT
CGAAATGGTCATCAGAGAGCTTGAGGAAAAGTTTCGGTTTTAAAGTCTCTATGCAGACACAGACGGTCTCC
ATGCCACCATTCTTGAGCGGACGCTGAAACAGTCAAGAAAAAGGCAATGGAGTTCTTAAACTATATCAAT
CCCAAACCTGCCCGGCCTTCTCGAACTCGAATACGAGGGCTTCTACGTCAGGGGCTTCTTCGTCACGAAGAA
AAAGTACGCGGTTCATCGACGAGGAGGGCAAGATAACCACGCGCGGGCTTGAGATAGTCAGGCGCGACTGGA
GCGAGATAGCGAAGGAGACGCGAGGCGAGGGTTTTGGAGGCGATACTCAGGCACGGTGACGTTGAAGAGGCC
GTCAGAATTGTCAGGGAAGTCACCGAAAAGCTGAGCAAGTACGAGGTTCCGCCGAGAGAGCTGGTTATCCA
CGAGCAGATAACGCGCGAGCTCAAGGACTACAAGGCCACCGGCCCGCACGTAGCCATAGCGAAgCGTTTTGG
CCGCCAGAGGTGTTAAATCCGGCCCCGGAACGTGTGATAAGCTACATCGTTCTGAAGGGCTCCGGAAGGATA
GGCGACAGGGCGATTCCCTTCGACGAGTTTCGACCCGACGAAGCACAAGTACGATGCGGACTACTACATCGA
GAACCAGGTTCTGCCGGCAGTTGAGAGAATCCTCAGGGCCTTCGGCTACCGCAAGGAAGACCTGCGCTACC
AGAAGACGAGGCAGGTCGGGCTTGGCGCGTGGCTGAAGCCGAAGGGGAAGAAGAGTGA

FIG. 2.

JDF-3 DNA polymerase amino acid sequence (SEQ ID NO: 2)

Theoretical molecular weight: 90.3 kD

MILDVDYITENGKPVIRVFKKENGEFRIEYDREFEPYFYALLRDDS AIEEIKKITAERHGRVVVKRAEKV
KKKFLGRSVEVWVLYFTHPQDVPAIRDKIRKHPAVIDIYEYDIPFAKRYLIDKGLIPMEGEEELKLMSFDI
ETLYHEGEEFGTGPILMISYADESEARVITWKKIDLPYEVVSTEKEMIKRFLRVVKEKDPDVLITYNGDN
FDFAYLKKRCEKLGVSFTLGRDGSEPKIQRMGDRFAVEVKGRVHFDLYPVIRRTINLPTYTLEAVYEAVFG
KPKEKVYAEIATAWETGEGLERVARYSMEDARVTYELGREFFPMEAQLSRLIGQGLWDVSRSSSTGNLVEW
FLLRKAYERNELAPNKPDERELARRRGGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSPDTLNRE
GCRSYDVAPEVGHKFCDFPGFIPSLGNLLEERQKIKRKMKATLDPLEKNLLDYRQRAIKILANSYYGY
GYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYADTDGLHATIPGADAETVKKKAMEFLNYIN
PKLPGLLELEYEGFYVRGFFVTKKKYAVIDEEGKITTRGLEIVRRDWSEIAKETQARVLEAILRHGDVEEA
VRIVREVTEKLSKYEVPPEKLVIEHQITRELKDYKATGPHVAIAKRLAARGVKIRPGTVISYIVLKSGRI
GDRAIPFDEFDPTKHKYDADYYYIENQVLP AVERILRAFGYRKEDLRYQKTRQVGLGAWLKPKGKKK

FIG. 3.

JDF-3 DNA polymerase with intein sequence (SEQ ID NO: 3)

MILDVDYITENGKPVIRVFKKENGEFRIEYDREFEPYFYALLRDDSAIEE
IKKITAERHGRVVKVKRAEKVKKKFLGRSVEVWVLYFTHPQDVPAIRDKI
RKHPAVIDIYEDIPFAKRYLIDKGLIPMEGEEELKLSFDIETLYHEGE
EFGTGPILMISYADESEARVITWKKIDLPYEVVSTEKEMIKRFLRVVKE
KDPDVLITYNGDNFDFAYLKKRCEKLGVSFTLGRDGSEPQIORMGDRFAV Extein 1
EVKGRVHFDLYPVIRRTINLPTYTLEAVYEAVFGKPKEKVYAEIATAWE
TGEGLERVARYSMEDARVTYELGREFFPMEAQLSRLIGQLWDVSRSTG
NLVEWFLLRKAYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNI
VYLDFRSLYPSIIITHNVSPDTLNRGCRSYDVAPEVGHKFKCKDFPGFIP
SLLGNLLEERQKIKRKMKATLDPLEKNLLDYRQRAIKILAN

SLLPGEWVA
VIEGGKLRPVIRIGELVDGLMEASGERVKRDGDTEVLEVEGLYASPTGSP
RKPAQCR*KP**GTAMPGKFTE*LSTPEGGLSVTRGHS LFAYRDASLWR*
RGRRRFKPGDLLAVPSG*PSRRGGRGSTSLNCSSNCPRRKRPTCHRHSGK
GRKNFFRGMRLRTLRFWIFGEEKTGGRPGATWSTLRGLGYVKLRKIGYGVVD
REGLGKVPFRFYERLVEVIRYNGNRGEFIADFNALRPVLRIMMPEKELEEW Intein 1
LVGTRNGFRIRPFIEVDWKFAKLLGYVSEGSAGKWKNRTGGWSYSVRLY
NEDGSVLDDMERLARSSLGA*ARGELRRDFKEDGLHNLRGALRFTGREQE
GSVAYLHVP*GGPLGLP*GVLHRRRRRSPEQDGSALHQERASG*RPRPAP
ELAGRLSDKRPPRQGLQGLRERTALYRVPEAEERLTYSHVIPREVLEE
TSAGPSRRT*VTGNSSGWWKAGSSTRKGPVG*AGSSTGI*SSTGSRKSGR
KATRGTTSTT*ALRRTRTSGGLWVPLRAQX

SYGYGYGYARARWYCRECAES
VTAWGREYIEMVIRELEEKFGFKVLYADTDGLHATIPGADAETVKKKAME
FLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEEGKITTRGLEIVR
RDWSEIAKETQARVLEAILRHGDVEEAVRIVREVTEKLSKYEVPPEKLVI Extein 2
HEQITRELKDYKATGPHVAIAKRLAARGVKIRPGTVISYIVLKGSGRIGD
RAIPDFDEFDPKHKYDADYYIENQVLPAPERILRAFGYRKEDLRYQKTRQ
VGLGAWLKPKGKKK

FIG. 4.
JDF-3 DNA polymerase genomic sequence (SEQ ID NO: 4)

AATTCCACTGCCGTGTTTAACTTTCCACCGTTGAACTTGAGGGTGATT
TCTGAGCCTCCTCAATCACTTAATCGAGACCGCGATTACCTTGAAGTGG
TACACGTTCAACGATTCGGTTCTTGTAAATGGTCGATACTGGGCCGTGCTG
GATTTTCTAAACGTCTCAAGAACGGCTTTCATCAACGGAACTGCCACGT 5' untranslated sequence
CTCCGCCGTGCTGAGGGTTAAACCTGAAGTTCAAGACTTTGCAACGGAAT
GGCGAGAGAACGGCGACTACCCAGTGAAGAGCTTTTGAAAGCCAAAGC
CGAGCTTCAGCGAATGTGCGGTGCCCTTGTTCAGAGTTGTGAGCCCTTG
ATTGTTGTTTTCTCCTCTTTTCTGATAACATCGATGGCGAAGTTTATTAG
TTCTCAGTTCGATAATCAGGCAGGTGTTGGTC

ATGATCCTTGACGTTGAT
TACATCACCGAGAATGGAAAGCCCGTCATCAGGGTCTTCAAGAAGGAGAA
CGGCGAGTTTCAAGATTGAATACGACCGCGAGTTGAGCCCTACTTCTACG
CGCTCCTCAGGGACGACTCTGCCATCGAAGAAATCAAAAAGATAACCGCG
GAGAGGCACGGCAGGGTCGTTAAGGTTAAGCGCGCGGAGAAGGTGAAGAA
AAAGTTCTTCGGCAGGTCTGTGGAGGTCTGGGTCTCTACTTCACGCACC
CGCAGGACGTTCCGGCAATCCGCGACAAAATAAGGAAGCACCCCGCGGTC
ATCGACATCTACGAGTACGACATACCCTTCGCCAAGCGCTACCTCATAGA
CAAGGGCCTAATCCCGATGGAAGGTGAGGAAGAGCTTAAACTCATGTCTT
TCGACATCGAGACGCTCTACCACGAGGGAGAAGAGTTTGAACCGGGCCG
ATTCTGATGATAAGCTACGCCGATGAAAGCGAGGCGCGCTGATAACCTG
GAAGAAGATCGACCTTCCTTACGTTGAGGTTGTCTCCACCGAGAAGGAGA
TGATTAAGCGCTTCTTGAGGGTCGTTAAGGAGAAGGACCCGGACGTGCTG
ATAACATACAACGGCGACAACCTTCGACTTCGCCTACCTGAAAAAGCGCTG
TGAGAAGCTTGGCGTGAGCTTTACCCTCGGGAGGGACGGGAGCGAGCCGA Extein 1
AGATACAGCGCATGGGGGACAGGTTTGCGGTGAGGTGAAGGGCAGGGTA
CACTTCGACCTTTATCCAGTCATAAGGCGCACCATAAACCTCCCGACCTA
CACCTTTGAGGCTGTATACGAGGCGGTTTTTCGGCAAGCCCAAGGAGAAGG
TCTACGCCGAGGAGATAGCCACCGCTGGGAGACCGGCGAGGGGCTTGAG
AGGGTCGCGCGCTACTCGATGGAGGACGCGAGGGTTACCTACGAGCTTGG
CAGGGAGTTCTTCCCGATGGAGGCCAGCTTTCAGGCTCATCGGCCAAG
GCCTCTGGGACGTTTCCCGCTCCAGCACCGGCAACCTCGTCGAGTGGTTC
CTCCTAAGGAAGGCCCTACGAGAGGAACGAACTCGCTCCCAACAAGCCCGA
CGAGAGGGAGCTGGCGAGGAGAAGGGGGGGCTACGCCGTTGGCTACGTCA
AGGAGCCCGAGCGGGGACTGTGGGACAATATCGTGTATCTAGACTTTCGT
AGTCTCTACCTTCAATCATAATCACCCACAACGTCTCGCCAGATACGCT
CAACCGCGAGGGGTGTAGGAGCTACGACGTTGCCCCGAGGTGCGTCA
AGTTCTGCAAGGACTTCCCGGCTTCAATCCGAGCCTGCTCGGAAACCTG
CTGGAGGAAAGGCAGAAGATAAAGAGGAAGATGAAGGCAACTCTCGACCC
GCTGGAGAAGAATCTCCTCGATTACAGGCAACGCGCCATCAAGATTCTCG
CCAAC

AGCCTTCTTCCCGGGAGTGGGTTGCGGTCAATTGAAGGGGGGAAA
CTCAGGCCCCGTCCGCATCGGCGAGCTGGTTGATGGAAGCCAG
CGGGGAGAGGGTGAAAAGAGACGGCGACACCGAGGTCTTGAAGTCGAGG
GGCTTTACGCTCTCCTTCGACAGGGAGTCCAAGAAAGCCCGCACAAATGC
CGGTGAAAGCCGTGATAAGGCACCGCTATGCCGGGGAAGTTTACAGAATA
GCTCTCAACTCCGGAAGGAGGATTAAGCGTGACGCGCGGCCACAGCCTCT
TCGCGTACCGGGACGCGAGCTTGTGGAGGTGACGGGGGAGGAGGAGTTT
AAGCCCGGCGACCTCCTGGCGGTGCCAAGCGGATAACCCTCCCGGAGAGG Intein 1

AGGGAGAGGCTCAACATCGTTGAACTGCTCCTCGAACTGCCCCGAGGAGGA
AACGGCCGACATGTCATCGACATTCCGGCAAGGGTAGAAAGAACTTCTTC
AGGGGAATGCTCAGAACCCTCCGCTGGATTTTCGGGGAGGAGAAGACCGG Intein 1
AGGGCGGCCAGGCGCTACCTGGAGCACCTTGCGTGGGCTCGGCTACGTGA
AGCTGAGGAAAATCGGCTACGGGGTGGTTGATAGGGAGGGACTGGGAAAG
GTACCGCGCTTCTACGAGAGGCTCGTGAGGTAATCCGCTACAACGGCAA
CAGGGGGGAGTTTCATCGCCGATTTCACGCGCTCCGCCCCGTCTCCGCC
TGATGATGCCCCGAGAAGGAGCTTGAAGAGTGGCTCGTTGGGACGAGGAAC
GGGTTTCAGGATAAGGCCGTTTCATAGAGGTTGATTGGAAGTTCGAAAAGCT
CCTCGGCTACTACGTGAGCGAGGGGAGCGCCGGGAAGTGGAAAAACCGGA
CCGGGGGCTGGAGCTACTCGGTGAGGCTTTACAACGAGGACGGGAGCGTT
CTCGACGACATGGAGAGACTCGCGAGGAGTTCTTTGGGGGCGTGAGCGCG
GGGGGAACTACGTGAGATTTCAAAGAAGATGGCCTACATAATCTTCGAG
GGGCTCTGCGGTTACCCGGCCGAGAACAAGAGGGTTCCGTGGCTTATCTT
CACGTCCCCTGAGGAGGTCCGCTGGGCCTTCCTTGAGGGGTACTTCATCG
GCGACGGCGACGTTACCCGAGCAAGATGGTTCCGCTCTCCACCAAGAGC
GAGCTTCTGGCTAACGGCCTCGTCTGCTCCTGAACTCGCTGGGCGTCTC
AGCGATAAACGTCCGCCACGACAGCGGGGTTTACAGGGTCTACGTGAACG
AGGAACTGCCCTTTACAGAGTACCGGAAGCGGAAGAAGCGCTCACTTACT
CCCACGTACATCCGAGGGAAGTGTGAGGAGACTTCGGCCGGGCCTTCC
AGAAGAACATGAGTCACGGGAAATTCAGGGAGCTGGTGGAAAGCGGGGAG
CTCGACGCGGAAAGGGCCGTTAGGATAGGCTGGCTCCTCGACGGGGATAT
AGTCCTCGACAGGGTCTCGGAAGTCAGGAAGGAAAGCTACGAGGGGTACG
TCTACGACCTGAGCGTTGAGGAGGACGAGAACTTCTGGCGGGCTTTGGGT
TCCTCTACGCGCACAAACNN

AGCTACTACGGCTACTACGGCTATGCCAGGG
CAAGATGGTACTGCAGGGAGTGCGCCGAGAGCGTTACGGCATGGGGAAGG
GAGTACATCGAAATGGTCATCAGAGAGCTTGAGGAAAAGTTCGGTTTTAA
AGTCCTCTATGCAGACACAGACGGTCTCCATGCCACCATTCTTGAGCGG
ACGCTGAAACAGTCAAGAAAAGGCAATGGAGTTCTTAAACTATATCAAT
CCCAAACCTGCCCGGCCTTCTCGAACTCGAATACGAGGGCTTCTACGTCAG
GGGCTTCTTTCGTACGAAGAAAAGTACGCGGTCTCGACGAGGAGGGCA
AGATAACCACGCGCGGGCTTGAGATAGTCAGGCGCGACTGGAGCGAGATA
GCGAAGGAGACGCAGGCGAGGGTTTTTGAGGCGATACTCAGGCACGGTGA Extein 2
CGTTGAAGAGGCCGTGAGAATTGTCAGGGAAGTCACCGAAAAGCTGAGCA
AGTACGAGGTTCCGCCGGAGAAGCTGGTTATCCACGAGCAGATAACGCGC
GAGCTCAAGGACTACAAGGCCACCGCCCCGACGTAGCCATAGCGAAGCG
TTTGCCCGCCAGAGGTGTTAAAATCCGGCCCCGAACTGTGATAAGCTACA
TCGTTCTGAAGGGCTCCGGAAGGATAGGCGACAGGGCGATTCCCTTCGAC
GAGTTCGACCCGACGAAGCACAAGTACGATGCGGACTACTACATCGAGAA
CCAGGTTCTGCCGGCAGTTGAGAGAATCCTCAGGGCCTTCGGCTACCGCA
AGGAAGACCTGCGCTACCAGAAGACGAGGCAGGTGGGCTTGGCGCGTGG
CTGAAGCCGAAGGGGAAGAAGTGA

GGAATTATCTGGTTTCTTTTCCC
AGCATTAATGCTTCCGACATTGCCTTATTTATGAACTCCTGTTGTGCC
TGAGTTTGTGCCAGAAAACAGCCTGTTCTGACGGCGCTTTTTCTTGCCAG
GTCTCTTGAGTTTCGAAGGGTCTTCTCGACCAGCTCAATGGTCTTGTGCG
TCATTGTTTNNNNNNNNNNNNNNNNNNNNNNCCGGGGACTTCATACTGGC
GGTAATAGACAGGGATTCTTCTCAAGGACTTCCCGGGAGGCATTGGAG
TTTTTTGGTGGGGCTTTCACAGGATTTGCTCATCTTGTGGATTTCTCGTT
CGATTGAATCTGTCCACTTGAGGGTGTAGGTGAGACGGTGGAGCGCGTA

TTCCGGGAGCGGGTCTTGAGGCTCCATTTTTTCAGTCCTCCTCCGGCGAAG 3' Untranslated sequence
AAGTGGAACCTCAAGCCGGGTGTTAGCTTATGTTATGTTCCCAACTCCTCC
AGCACCTCCAGGATCCCCCTCAATCCCGGAACCTCGAAGCCCCCTCTCGTGG
ATCTTTCTAACTTCTCTGCCTCCGGGTTTATCCAGACCGCCACATGCC
GGCTCTCAGCGCACCCCTCGAAATCCTCCGCGTAGGTGTCGCCGATGTGGA
TTGCCCTCGTCCGGCTCGACCCCGAAGCATCGAGCGGTTTTCTGAACATCT
CGGGCATCGGCTTATACGCCAGAACCTCGTCGGCGAAGAAGGTTCCCTCA
ATGTAGTCCATCAGGCCGAACCTCTCGAGGGGGGGCCCGGTACCCAATTC
GCCCTATAGTGAGTCGATTACAATTCACTGGCCGTCGTTTTACAACGTCG
TGA CTGGGAAAACCTGGCGTTACCCA ACTTAAGTCGCTTTGCAGCACAT
CCCCC

Preliminary Qualification of Mutants




Figure 5

Sequencing with Purified Mutants




Figure 6

Sequencing with Dye-labeled Dideoxynucleotides




Figure 7

Sequencing with the P410L, A485T Double Mutant and α -³³P Dideoxynucleotides





Figure 8

Figure 9






Figure 10




Figure 11

^{33}P - TAACGTTGGGGGGGGGGCA →
 TGCAACCCCCCCCCCGTAT




Figure 12

Flu ddUTP signal/ddTTP signal




Figure 13

4	1	-----LVXNAXSTGNLVEWFLLRK
10	1	-----VWDVSRSTGNLVERFLLRK
13	1	-----VWDVSRSTGNLVEWFLLRK
16	1	-----VWDVSRSTGNLVEWFLLRK
18	1	-----VWDVSRSTGNLVEWFLLRK
19	1	-----VWDVSRSTGNLVEWFLLRK
28	1	-----VWDVSRSTGNLVEWFLLRK
34	1	-----VWDVSRSTGNLVEWFLLRK
41	1	-----VWDVSRSTGNLVEWFLLRK
33	1	-----VWDVSRSTGNLVEWFLLRK
48	1	-----VWDVSRSTGNLVEWFLLRK
55	1	-----YWSXPXLRTGNLVEWFLLRK
64	1	-----VIGTXPRSSTGNLVEWFLLRK
Jdf3	301	TGEGLERVARYSMEDARVTYELGREFFPMEAQLSRLIGQGVWDVSRSTGNLVEWFLLRK

4	20	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
10	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHSVSP
13	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
16	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
18	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
19	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
28	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
34	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
41	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
33	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
48	21	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
55	22	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
64	24	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP
Jdf3	361	AYERNELAPNKPDERELARRRGYAGGYVKEPERGLWDNIVYLDFRSLYPSIIITHNVSP

4	80	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
10	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
13	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
16	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
18	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
19	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
28	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
34	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
41	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
33	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
48	81	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
55	82	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
64	84	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD
Jdf3	421	DTLNREGCRSYDVAPEVGHKFKDFPGFIPSLLGNNLEERQIKRKMKATLDPLEKNLLD

Figure 14

4	140	YRQRAIKILANSYYGYGCGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
10	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
13	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
16	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
18	141	YRQRAIKILANNYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
19	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
28	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
34	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
41	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
33	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
48	141	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
55	142	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
64	144	YRQRAIKILANSYYGNYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD
Jdf3	481	YRQRAIKILANSYYGYGYGYARARWYCRECAESVTAWGREYIEMVIRELEEKFGFKVLYAD

4	200	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
10	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
13	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
16	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
18	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
19	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
28	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
34	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
41	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
33	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
48	201	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
55	202	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
64	204	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE
Jdf3	541	TDGLHATIPGADAETVKKKAMEFLNYINPKLPGLLELEYEGFYVRGFFVTKKKYAVIDEE

4	260	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
10	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
13	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
16	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
18	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
19	261	GKITTRGLEIVRRDWSKIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
28	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
34	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
41	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
33	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
48	261	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
55	262	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
64	264	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL
Jdf3	601	GKITTRGLEIVRRDWSEIAKETQARVLEAAILRHGDVEEAVRIVREVTEKLSKYEVPPEKL

Figure 15

DECLARATION AND POWER OF ATTORNEY
FOR A PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

“COMPOSITIONS AND METHODS UTILIZING DNA POLYMERASES”

the specification of which:

(check one) ☒ [X] is attached hereto.

☐ [] was filed on _____ as

Application Serial No. _____
and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I do not know and do not believe that the invention was ever patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application.

I do not know and do not believe that the invention was in public use or on sale in the United States of America more than one year prior to this application.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

Priority
Claimed

60/162,600
(Number)

US
(Country)

29/10/99
(Day/Month/Year filed)

☐ ☐
Yes No

<u> </u> (Number)	<u> </u> (Country)	<u> </u> Day/Month/Year filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No
---	--	--	------------------------------	-----------------------------

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States Patent application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status: patented/pending/abandoned)

(Application Serial No.) (Filing Date) (Status: patented/pending/abandoned)

(Application Serial No.) (Filing Date) (Status: patented/pending/abandoned)

As a named inventor, I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:


Kathleen M. Williams, Reg. No. 34,380
Paula A. Campbell Evans, Reg. No. 32,503
Richard B. Smith, Reg. No. 34,020
Elizabeth N. Spar, Reg. No. 45,123
Mark J. Fitzgerald, Reg. No. 45,928
John Garvey, Reg. No. 37,833

Send Correspondence to: Kathleen M. Williams, Esq.
Palmer & Dodge, LLP
One Beacon Street, Boston, MA 02108-3190

Direct telephone calls to: Kathleen M. Williams at telephone: (617) 227-0451

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Joseph A. Sorge


First Inventor's signature

10/18/00
Date

Residence United States

Citizenship United States

Post Office Address 5320 Pine Meadow Road, Wilson, WY 83014

Full name of second inventor Holly Hurlbut Hogrefe


Second Inventor's signature


10/6/00
Date

Residence United States

Citizenship United States

Post Office Address 6045 Dirac Street, San Diego, CA 92122

Full name of third inventor Connie Jo Hansen


Third Inventor's signature

10/10/00
Date

Residence United States

Citizenship United States

Post Office Address 3645 Gayle Street, San Diego, CA 92115